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Gliomas are responsible for a disproportionate share of cancer-related morbidity and 
mortality, despite being less common than other cancers, so treatments for glioma 
patients are a serious unmet need. About 3% of gliomas harbor either constitutively 
activating point mutations or fusions in the gene BRAF which activate the BRAF-
MEK-ERK pathway. Because there are specific inhibitors for this pathway available, 
in this work we interrogated the underling biology of the sensitivity of BRAF-mutant 
gliomas to these inhibitors. We identified cell lines with BRAF mutations and showed 
that BRAF-V600E gliomas are dependent on BRAF signaling and MEK kinase 
activity for tumor maintenance. Next we showed that the monomeric BRAF inhibitor 
vemurafenib is able to inhibit mutant-BRAF signaling in glioma, However, this 
inhibition is transient, and ERK phosphorylation quickly rebounds. This ERK rebound 
is associated with incomplete inhibition of Cyclin D1 and lack of growth suppression. 
We then sought to identify possible candidate RTKs that were upregulated by relief of 
ERK-dependent feedback and might reactivate ERK signaling. We found that ERBB 
family members and their activity were upregulated. However, we also found that 
EGFR and HER2 kinase activity does not appear to be necessary in order to induce 
ERK rebound. We then looked into the role of negative feedback on RAS signaling 
and showed that vemurafenib relieves negative feedback on RAS signaling, leading to 
increases in RAS-GTP and the induction of a vemurafenib insensitive state. However, 
   
drugs that target the RAF dimers that are a product of increased RAS-GTP are able 
potently suppress ERK rebound, Cyclin D1 expression, and achieve greater growth 
suppression. Finally, we tried to understand the role of the RAS-GAP NF1 in GBM. 
We established and biochemically validated an inducible NF1 expression system and 
examined its biological role. Interestingly, NF1 expression is not growth suppressive 
in all NF1-deficient cell lines. Despite this, NF1-deficient cell lines appear to maintain 
a MEK dependency that can be therapeutically targeted with a MEK inhibitor, even 
though NF1 reconstitution has little direct effect on MEK and ERK signaling. 
Together, this works describes alterations at two different nodes of the MAP-Kinase 
pathway and their therapeutic relevance. 
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CHAPTER 1: INTRODUCTION 
 
PART 1 – Cancer and glioma 
 
Cancer is a collective term for a group of related diseases that, on a simplified 
level, are commonly defined by uncontrolled cellular proliferation. Hanahan and 
Weinberg defined “hallmarks of cancer” that cells collect as they progress from a 
normal, non-neoplastic state to become tumorigenic and cancerous (Hanahan and 
Weinberg 2011). The six primary hallmarks are:  
1. sustained proliferative signaling; 
2. the evasion of growth suppressive signaling; 
3. activating invasive and metastatic programs; 
4. circumventing normal programs of senescence to achieve replicative 
immortality;  
5. inducing angiogenesis, the formation of blood vessels to feed tumors;  
6. and resisting cell death.  
Though benign tumors can arise in nearly any tissue type of the body and can possess 
many of these traits, a growth must achieve all of these hallmarks to progress to a 
frank cancer. 
Tumors of the central nervous system, collectively known as “malignant gliomas,” 
are a heterogeneous mix of tumors that occur within the tissues of the brain or spinal 
cord. Despite being relatively uncommon, totaling approximately 22,500 cases 
worldwide, they are a disproportionate cause of cancer-related morbidity and mortality 
(Wen and Kesari 2008). The majority of gliomas (estimated to be about 60 to 70%) 
are glioblastomas, with the remainder split between anaplastic astrocytomas (about 10 
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to 15%), and anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (also 
about 10%-15%). While almost all gliomas fall into these categories, there are still 
many other rare types of gliomas that still occur with some frequency. 
Since the 1950s, neurologists have worked to devise a universal classification 
system for tumors of the central nervous system (Ringertz 1950). The World Health 
Organization’s (WHO) classification system was first codified in 1980 (Zülch 1980) 
and last updated in 2007 (Louis et al. 2007). According to the WHO classification 
system, tumors are classified based on their anatomical location within the CNS and 
according to their histopathological features. From there, tumors are assigned to one of 
four grades, from Grade I (low proliferative potential, not malignant) to grade IV 
(highly proliferative and invasive, most malignant). 
Grade I and II tumors are known as low-grade glioma, while grade III and IV 
tumor are known as high-grade gliomas (Louis et al. 2007). Low grade gliomas are 
very diverse. Some, like pilocytic astrocytoma (discussed below) are highly 
circumscribed and indolent. Others are more diffuse and infiltrative, and tend to be 
difficult to resect. Prognosis in low grade gliomas is also diverse, as some tumors will 
remain stable for even fifteen years, while others will progress to higher grade gliomas 
within a matter of months.  
The symptoms that arise from most gliomas share a common etiology. As physical 
space inside the cranium is limited, gliomas induce symptoms by placing pressure on 
normal brain tissue, thereby impairing normal brain function, leading to seizures, 
headache, and other neurological symptoms like memory loss, personality change, 
confusion, speech problems. If tumors occur in critical areas, these symptoms can be 
quite severe and life threatening, even if the tumor itself is not highly malignant. 
Because higher grade tumors grow so much quicker and are more invasive and 
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malignant, they tend to result in morbidity and mortality on a much more accelerated 
time scale than in lower grade gliomas.  
Pilocytic astrocytoma (PA) is a grade I glioma that is typically indolent and whose 
tumor borders are very well circumscribed that most frequently occurs in young 
children. Although surgical treatment can be curative, if tumors occur in surgically 
inaccessible locations or recur following resection, they can be associated with 
morbidity and mortality. Patients with mutations in the neurofibromin 1 (NF1) gene 
are at increased risk for PA as well as for optic pathway gliomas, a tumor of the 
cellular sheaths of the optic nerves. Of note, is is thought that neurofibromin (NF1), 
the protein product of the NF1 gene, is thought to control the RAS-ERK signaling 
pathway (discussed in greater detail later). Interestingly, activating point mutations or 
gene fusions of the BRAF or RAF1 genes are also frequently occur in PA, and the 
RAF genes are integral members of the RAS-ERK pathway, underscoring the 
importance of this signaling pathway in the pathogenesis of the disease. 
The most common primary brain tumor is glioblastoma (GBM), a grade IV tumor. 
GBM most frequently occurs in patients over the age of 50.  Originally, high grade 
gliomas like GBM were aggressively treated with surgical resection to the fullest 
extent possible and ionizing radiation. However, these therapies remain mostly 
ineffective. Because GBM is highly invasive, surgical resection is invariably 
incomplete, leading to a regrowth of the original tumor (then diagnosed as recurrent 
GBM). In 2005, a Phase III clinical trial showed a clear benefit to adding the 
nitrosourea alkylating agent temozolomide (TMZ), resulting in significantly longer 
overall survival and progression-free survival (Stupp et al. 2005). Despite this 
important advance, overall median survival for newly diagnosed GBM remains at 12-
18 months and is still nearly universally fatal (Cloughesy et al. 2014). Indeed, GBM is 
resistant to most other standard cytotoxic chemotherapeutic agents, and frequent 
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alterations can often lead to de novo resistance to temozolomide (TMZ), currently the 
only FDA approved chemotherapy for GBM. Shortly after TMZ was added to the 
standard of care in GBM, it was demonstrated that the MGMT gene promoter, which is 
typically epigenetically silenced, can lead to de novo resistance to TMZ when active 
(Hegi et al. 2005). 
Before 2008, knowledge of these such molecular alterations was fragmentary, but 
included dysregulation of growth factor signaling through mutation and activation of 
receptor tyrosine kinases (RTKs), frequent activation of the phosphatidylinositol-3-
OH kinase (PI3K) pathway, and inactivation of the Rb and p53 tumor suppressor 
pathways. Without a unified approach to the frequency, co-occurrence, or mutual 
exclusivity of these alterations and because of the lack of therapeutic options 
available, GBM was selected as for the pilot project of The Cancer Genome Atlas 
(TCGA). The aim of TCGA was to catalog the genomic alterations present in cancer 
genes across many samples of a given type of cancer. 
The results of the TCGA project confirmed the dysregulation of these pathways, 
but revealed that they occurred for diverse and often different reasons. Indeed, the 
PI3K pathway could be hyperactivated through somatic mutation of PI3K genes (like 
PIK3CA), deletion of PTEN, amplification of AKT genes, or somatic mutation of 
FOXO genes, transcriptional effectors of the PI3K pathway (Cancer Genome Atlas 
Research Network 2008). 80-90% of the tumors surveyed had some recorded mutation 
in the RB, TP53, and RTK pathways and these pathway alterations tended to be highly 
mutually exclusive. Despite being treated as one disease in the clinic, this suggested 
that GBM might actually be able to be further subclassified.  
The next TCGA project in GBM included transcriptomic analysis of tumors in 
addition to the genomic analysis performed in the pilot project (Verhaak et al. 2010). 
Gene expression profiling and hierarchical classification of the resulting data showed 
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that GBM could be broadly classified into one of four subtypes, each of which was 
typified by a different genomic alteration. Following the addition of genome-wide 
methylation data, GBM is now classified into one of six molecular subgroups (Sturm 
et al., 2012). The first two subtypes are pediatric GBMs associated with two mutations 
in the histone gene H3F3A (encoding histone H3.3). The third subgroup, termed 
proneural, is characterized by point mutation in the isocitrate dehydrogenase 1 (IDH1) 
gene. This subgroup most frequently manifests in young adults whose IDH1 mutated 
tumors progressed from grade II or II gliomas. The fourth group, termed “RTK I” 
includes tumors with alterations in platelet derived growth factor α (PDGFRA) and a 
proneural expression pattern. The fifth, termed “RTK II” or classical, is characterized 
by frequent epidermal growth factor receptor (EGFR) gene amplification. The sixth, 
termed mesenchymal, is defined by loss of NF1 function through mutation or deletion.  
Of note, in the subtypes identified by Verhaak (classical, neural, proneural, and 
mesenchymal), aggressive treatment resulted in better overall survival in the classical 
and mesenchymal subgroups, while it was less effective in the neural subgroup, and 
had no effect on the proneural subgroup. This suggested that clinicians could spare 
patients from a chemotherapeutic regimen that would be both unsuccessful and 
detrimental to quality of life. 
As the TCGA expanded beyond GBM to other cancer types, the catalogue of 
genomic alterations found in tumors became ever more complex. As scientists and 
clinicians observed that tumors could harbor even hundreds or thousands of mutations 
and chromosomal aberrations, the field began to fear that it might be impossible to use 
this data to guide therapeutic decisions. However, preclinical experiments showed that 
despite possessing a constellation of genomic alterations, many tumors were in fact 
exquisitely dependent on a single oncogene, a phenomenon termed oncogene 
addiction (Weinstein and Joe 2008). One of the earliest examples of the therapeutic 
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exploitation of oncogene addiction was the development of the drug imatinib 
(Gleevec).  
After clinicians observed that over 90% of chronic myeloid leukemias possessed a 
chromosomal translocation between the BCR and ABL kinase genes (BCR-ABL) 
resulting in a constitutively active ABL kinase that was both necessary and sufficient 
for leukemogenesis (Daley et al. 1990). Hypothesizing that one might be able to 
inhibited the kinase activity of the dysregulated ABL kinase with a small molecule, 
Novartis developed the drug imatinib (brand name Gleevec.) The pivotal Phase III 
clinical trial recorded an almost 90% response rate, and most importantly, was very 
well tolerated, as the drug carried none of the typical side effects of cytotoxic 
chemotherapeutic regimens (O’Brien et al. 2003) in a disease that was universally fatal 
within months following diagnosis. 
Quickly following imatinib was the introduction of trastuzumab (brand name 
Herceptin) which targeted human epidermal growth factor receptor type 2 (HER2) 
which was highly overexpressed in a subset of breast cancers (Eiermann, 2001). In 
trastuzumab’s pivotal Phase III trial, the response rate was raised from 32% to 49% 
when compared to standard of care chemotherapy, a major milestone in the treatment 
of a disease that used to have dismal survival prospects.  
These early trials establish proof of concept for the development of molecularly 
targeted therapeutics, and researchers, drug makers, and clinicians quickly ramped up 
efforts to find “druggable” alterations. EGFR is one of the most frequently altered 
genes in GBM, with high level copy amplification (2008), activating point mutations 
in the extracellular domain (Vivanco et al., 2012), and deletions of exon 2-7 in the 
extracellular domain (a specific mutation known as EGFRvIII). Despite impressive 
response rates and success in EGFR mutant lung cancers (Lynch et al., 2004), EGFR 
inhibitors have failed to achieve much success in GBM. (Mellinghoff et al., 2005). 
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showed that in clinical trials of the EGFR inhibitor erlotinib or gefitinib, only patients 
that expressed EGFRvIII and had intact copies of phosphatase and tensin homologue 
deleted in chromosome 10 (PTEN) had demonstrable responses.  
 
PART 2 – Signal transduction 
 
The cells of all multicellular organisms require the means to communicate with 
each other in order to coordinate information about proliferation, metabolism, and 
differentiation across the whole of the organism. This process is known as “signal 
transduction.” Signal transduction has several major steps that can be generalized 
across many pathways and purposes (Hendrickson, 2005). As a cell determines that it 
needs to communicate some piece of information, that cell must first synthesize, and 
then release a “signal.” That signal, which can be molecules including amino acids or 
peptides or metabolic products, must then be transported to a target cell. That cell 
must then detect the presence of that signal, usually through a receptor protein. The 
receptor-signal complex then triggers a change in the target cell. Finally, once it has 
served its purpose, the signal must then be removed to terminate the cellular response. 
Cellular signaling in multicellular organisms is classified by the distance that the 
signal travels. Endocrine signals travel over long distances to distant cells while 
paracrine signaling acts on nearby or adjacent cells. Some cells also signal to 
themselves, a process termed autocrine signaling (Hendrickson, 2005).  
A receptor protein exhibits a fit, or affinity, for certain signals, or ligands. This 
means that receptors tend only to transmit signals when bound by specific ligands. 
After doing so, receptors then undergo a conformational change that start a chain of 
reactions to propagate the signal through the cell in order to effect change. These 
reactions typically move through so-called second messengers, which amplify the 
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signal and help to specify the specific action the cell should take in response to the 
ligand (McCormick and Baillie, 2014).  
Receptors are classified based on their location. Some ligands, especially those 
that are highly lipophilic, readily diffuse across the cell’s plasma membrane and bind 
to intracellular receptor proteins (Hendrickson, 2005). These ligand-receptor 
complexes then translocate to the nucleus and act as transcription factors to cause 
transcriptional changes. Other ligands which are more hydrophilic cannot diffuse 
across the plasma membrane and bind to receptor proteins that are embedded within it 
(transmembrane receptors). These transmembrane receptors fall into three categories. 
G-protein coupled receptors (GPCRs) use a G protein that is released from the signal-
receptor complex which then modulates second messengers. Ion-channel receptors 
change conformation following ligand binding to permit the flow of charged ions 
along their concentration gradients and change cellular potential. The final category 
are receptors with intrinsic enzymatic activities, such as receptor tyrosine kinases 
(RTKs). 
Following stimulation of a receptor, cells often employ a “second messenger.” 
Second messengers are typically small molecular weight molecules generated through 
enzymatic activity (such as cyclic adenosine monophosphate, cAMP) or are stored 
inside the cell and released (such as Ca2+ ions). Second messengers are usually 
generated locally, resulting in an increase in their concentration. The elevated local 
concentration of these second messengers can trigger a diverse array of cellular 
activities, but they mainly serve to amplify a local message, and propagate it through 
the cell to eventually effect the change that the original signal was intended for. 
Indeed, as individual steps in signaling cascades are often enzymatic in nature, each 
one can increase the size of the signal by orders of magnitude, allowing very small 
inputs to effect great change in both individual cells as well as across the many tissues 
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of an organism. They also are free to diffuse throughout the cytosol of the cell where 
they can then effect changes in geographically distant regions of the cell.  
Finally, the signal must be removed in order to keep it from perpetually signaling. 
This can be done through several means. Small molecular components of the signaling 
process, such as peptides or second messenger molecules like cAMP can be degraded 
by enzymes specific to those molecules. Activated receptors are subject to 
dephosphorylation by phosphatases as well as to ubiquitination and subsequent 
targeting of the receptor to the proteasome for degradation.  
 
Kinases are a diverse group of proteins, of which there are thought to be 500 
members of in the human genome (Zhang et al., 2009). The primary role of a kinase is 
to catalyze the enzymatic transfer of a phosphate group from the donor molecule 
adenosine triphosphate (ATP) to a recipient protein. Charged phosphate groups carry a 
formal charge of negative two, and when covalently attached to proteins, induce 
structural changes through affecting hydrogen bonding networks and changing the 
conformation of protein-interaction surfaces. These conformational changes can affect 
the activity of the recipient protein, thereby activating or inactivating it, or modulating 
its activity to some degree. 
The active site of kinases, known as the ATP binding site, is located between two 
“lobes,” a N-terminal lobe with of a β-sheet and a single α-helix, and a mostly α-
helical C-terminal lobe, connected by a linker region (Endicott et al., 2012). The C-
terminal lobe contains the “activation segment” which contains a highly conserved 
DFG motif (where each letter refers to the single letter amino acid abbreviations) that 
chelates a Mg2+ ion when in the active formation which in turn positions a molecule of 
ATP for optimal catalysis. The activation segment is often phosphorylated in order to 
promote the active conformation of the kinase. In the inactive conformation, the 
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activation segment becomes disordered and often turns its phenylalanine towards the 
ATP binding site to block it. 
Substrate recognition and specificity employ two different types of interactions. 
The first is the recognition of the individual kinase’s consensus motif in its preferred 
substrate. Although kinase domains are largely structurally conserved, they differ at 
key amino acid residues in the ATP binding pocket in order to guide the specificity of 
the kinase protein as a whole. These differences, discussed in greater detail below, are 
key to the discovery and synthesis of small molecular inhibitors of kinase activity. The 
second type of interaction that guides kinase specificity is mediated through diverse 
protein association and docking of more distal domains in both the kinase protein and 
its substrates.    
Humans possess the genes for 52 different RTKs, which include the 
aforementioned EGFR and HER2 (Lemmon and Schlessinger, 2010). RTKs are share 
a common structure with an extracellular, ligand-sensing domain, a single-pass helical 
transmembrane domain, and a cytoplasmic region that contains a tyrosine kinase 
domain along with more regulatory regions. RTKs also share a common activation and 
signaling mechanism. Canonically, RTKs are expressed as inactive monomers at the 
cell surface whose dimerization and subsequent activation are induced by ligand 
binding at the extracellular domain. However, it has become clear that some RTKs, 
like the insulin receptor, are actually expressed as constitutive heterodimeric 
complexes that remain inactive until ligand binding (Ward et al., 2007).  
Upon receptor dimerization or ligand activation of pre-existing oligomers, the 
kinase domain of one receptor typically phosphorylates the kinase domain of the other 
oligomer to activate it. The diversity of RTKs however is also reflected in the diversity 
of their dimerization and activation processes, and here the case of the insulin receptor 
is described. When in its inactive, non-ligand bound state, Y1162 of one kinase 
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activation segment of insulin receptor projects into the active site of its own kinase 
domain, as if poised to be phosphorylated, thereby blocking access to ATP and the 
kinase substrate (Endicott et al., 2012). When activated by insulin, conformational 
changes induce the kinase domain of one oligomer to trans-phosphorylate the other 
domain, thereby relieving its cis-autoinhibition. 
The primary substrates of RTKs are the trans-phosphorylation of each other on 
several sites. The kinase domain often contains several tyrosines that drastically 
change the enzymatic activity of the kinase (Lemmon and Schlessinger, 2010). 
Typically, the phosphorylation of these sites occurs in a precise order that each 
increase kinase activity. Next, “secondary” tyrosines are phosphorylated that act as 
docking sites to recruit other signaling molecules, forming assembly scaffolds 
responsible for carrying out further downstream signaling processes. Proteins that bind 
these phosphotyrosine motifs contain either Src homology-2 (SH2) domains or 
phosphotyrosine-binding (PTB) domains. These proteins are either directly recruited 
or indirectly associate through other proteins that become phosphorylated as part of 
the signaling cascade. Finally, in some RTKs, a tertiary set of tyrosines become 
phosphorylated that maximize the kinase activity of the kinase domain. RTKs can also 
contain a divesr array of other association domains that control the recruitment of 
proteins to the cell membrane through pleckstrin homology (PH) domains or to other 
proteins through domains like SH3 and PDZ domains. 
The differential presence and quantity of these domains is largely responsible for 
dictating the role of the RTK and its associated partners in downstream signaling. For 
instance, some RTKs will become differentially transphosphorylated under certain 
conditions and recruit different signaling complexes with altered signaling capabilities 
(Eck et al., 1996). Indeed, the signaling output from RTKs and their signaling network 
is less a linear pathway and more of a complex set of integrated nodes carefully 
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regulated by feedback. While this systems level approach to signaling pathways and 
networks has only recently begun to be mapped with the advent of gene expression 
arrays and phosphoproteomic tools, it has been long known that the exact same 
signaling components can be used to different effect. Short duration activation of the 
EGFR receptor with its ligand EGF in PC12 cells leads to proliferation, largely by 
stimulating the Mitogen Activated Kinase Pathway (MAPK). However, by 
overexpressing the EGFR receptor in these cells, EGF stimulation leads to more 
prolonged MAPK activation, followed by neurite outgrowth and cellular 
differentiation (Santos et al., 2007). 
 
Therefore, signal transduction through a more contemporary lens holds that 
signaling processes resemble an “hourglass” structure (Citri and Yarden, 2006). On 
top, the input layer is made up of many input RTKs and their diverse ligands which 
can result in a variety of strengths and durations of signaling. From there, these inputs 
move into a “conserved core processes” node where the input signals move through 
non-receptor kinase activity (including the MAPK pathway), phosphoinositide 
signaling (such as the PI3K pathway), small GTPase cycles (like RAS, discussed 
later), and the addition and removal of ubiquitin moieties (which can both regulate the 
activity of proteins and target them for degradation at the proteasome). These signals 
are then “read out” by a diverse output layer, resulting in transcriptional changes, 
cytoskeletal rearrangements, or other changes in cell-intrinsic properties. Most 
important to the systems level approach to signaling are the feedback mechanisms 
employed by the core processes that carefully regulate their activity. 
On some level, almost all signaling processes employ feedback in order to fine 
tune their magnitude and duration. Furthermore, the conserved processes also employ 
feedback between the many pathways as well, which is known as pathway crosstalk 
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(Citri and Yarden, 2006). Pathway crosstalk is important to signal transduction since 
so many different signaling processes employ the very same signaling machinery. On 
a general level, there are several kinds of feedback loops (Kolch et al., 2015). The first 
is positive feedback, where the product of a pathway further stimulates an earlier step, 
increasing the magnitude of signaling through the pathway. This is analogous to 
holding down the accelerator on a car. On its own, a positive feedback loop can result 
in runaway perpetual signaling, so they are used by cells in order to force 
commitments, such as progressing through the cell cycle after the restriction point, the 
point at which a cell commits to complete the cell cycle. Positive feedback adds 
robustness to signaling, especially in situations when signaling noise might complicate 
cell-fate decision that require commitment. It also allows a cell to react to very low 
abundance signals, amplifying them to biologically active levels. 
The second type is negative feedback, where the output of a pathway inhibits an 
earlier step, essentially attenuating signaling through the pathway up to completely 
turning it off. This is analogous to pressing on the brake of a car, slowing it down, and 
given enough time and force, eventually bringing it to a halt. In general negative 
feedback adds robustness to signal transduction, smoothing noise and sudden 
perturbations (Nguyen and Kholodenko, 2015). Depending on the strength and 
duration of both input signal and of the feedback, negative feedback can convert 
oscillating signals to a smooth input. Both positive and negative feedback loops work 
in tandem to order to translate signaling network dynamics into cell-intrinsic decisions 
in response to signals. Interestingly, many of the genes that regulate this feedback are 
often tumor suppressors or oncogenes, demonstrating their importance in cancer 
pathogenesis. 
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PART 3 – The RAS-ERK pathway components 
 
One of the most well described “core conserved” pathways is the RAS-mitogen 
activated protein kinase cascade (RAS-MAPK). It is composed of several proteins and 
successively activate each other in turn, culminating in many cellular actions including 
growth, proliferation, differentiation, senescence, and migration (Santarpia et al., 
2012). Its constituent members are the small GTPase KRAS, NRAS and HRAS 
(collectively referred to as RAS), the serine/threonine kinases c-Raf, ARAF, and 
BRAF (collectively referred to as RAF), MEK1 and MEK2 (named for MAPK/ERK 
Kinase, collectively referred to as MEK), and ERK1 and ERK2 (extracellular signal 
regulated kinases, collectively referred to as ERK). 
RAS was originally identified as gene components of tumor causing viruses in 
mice starting in the 1960s (Santarpia et al., 2012). Eventually, three different isoforms 
of Ras were identified, the first two named after their discoverers—HRAS, for 
Jennifer Harvey (Harvey, 1964); KRAS, for Werner Kirsten (Kirsten et al., 1970)—
while the third, NRAS, was identified in neuroblastoma cells. Several seminal papers 
of this era identified mutations in RAS genes as causative, transforming oncogenes in 
human cancer. Eventually, sequencing of the RAS  genes in human tumors 
demonstrated that up to a third of tumors harbored an activation mutation of RAS. 
With this, the field rapidly set out to understand RAS biology. 
The three human RAS genes code for four highly related protein products, namely 
HRAS, NRAS, KRAS4A and KRAS4B, which are alternative splicing products of the 
KRAS gene (Takashima and Faller, 2013). RAS is a small GTPase that acts as 
molecular switch, alternating between an inactive GDP-bound state and an active 
GTP-bound state. This processes, while thermodynamically favorable, are highly 
inefficient, so they are largely controlled by the presence of external factors. When 
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activated by guanine exchange factors (GEFs), RAS releases bound GDP and binds 
GTP, which is found at a higher intracellular concentration. When bound by GTP, 
active RAS can then bind and activate downstream effector pathways. As a GTPase, 
RAS has an intrinsic hydrolytic activity. However, this enzymatic activity is greatly 
catalyzed by the enzymatic stimulation by GTPase activation proteins (GAPs). GAPs 
stimulate the hydrolysis of bound GTP, converting it to GSP and inactivating RAS. 
The proper functioning of RAS requires a certain set of posttranslational 
modifications in order for proper functioning. RAS is decorated with a farnesyl tail (a 
modified fatty acid) that is necessary for the localization of RAS to the inner leaflet of 
the cellular membrane (Takashima and Faller, 2013). This localization is important 
because GEFs are often activated by signaling receptors, like RTKs, which are also 
located in the cell membrane. As described before, ligand binding to RTKS leads to 
transautophosphorylation and the nucleation of phosphorylated binding sites for 
adaptor proteins. For EGFR, the protein GRB2  binds these sites through its SH3 
domain, which in turn recruits SOS, through its SH2 domain. SOS then acts a GEF, 
stimulating the activation of RAS and allowing it to engage its downstream effector 
pathways. 
RAS has several parallel effector pathways, many of which also have been 
independently  implicated in cancer. All of these effectors possess a RAS binding 
domain (RBD) that associated with active GTP-bound RAS. The most well described 
of these pathways include the MAPK pathway, the PI3K pathway, RAC, RALGDS, 
and phospholipase Cε (PLCε) (Downward, 2003). Activated RAS binds the catalytic 
subunit of PI3-Kinase which recruits it to the cell membrane and activates its lipid 
kinase activity, generating the second messenger PIP3 in the plasma membrane. 
Downstream of PIP3 activation, the protein kinases Akt and PDK1 are activated, 
which activate several anti-apoptotic pathways. RALGDS, itself also a small GTPase, 
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is activated when active RAS binds RALGDS’s exchange factors. RALGDS signaling 
inactivates the FORKHEAD family of transcription factors, which promote cell cycle 
arrest and are also proapoptoic. PLCε also has a RAS-binding domain, and links RAS 
signaling with protein kinase C (PKC) and Ca2+ mobilization. 
The MAPK pathways are well studied signaling cascades that transduce a variety 
of growth, proliferation, differentiation, developmental, and stress signals from 
membrane bound receptors to a namesake transcription factor (Zhang and Liu, 2002). 
There are currently four known MAPK pathways— ERK, JNK, p38 and BMK—
although there are possibly more, as many MAPK genes have been identified through 
homology searches, though their specific functions have yet to be elucidated. All 
MAPK pathways share a common structure, where a MAP-Kinase Kinase Kinase 
(MAP-KKK) phosphorylates and activates a MAP Kinase Kinase (MAP-KK) which 
in turn phosphorylates and activates a terminal MAP kinase (MAP-K). The best 
characterized of these pathways is the RAS-RAF-MEK-ERK (shortened to RAS-
ERK) pathway. 
The RAF family of genes is composed of CRAF (RAF1, also known as c-Raf and 
RAF1), ARAF (ARAF), and BRAF (BRAF). CRAF was originally identified as a 
proto-oncogene through induced mutagenesis experiments that invariably revealed N-
terminal truncations or rearrangements but an intact kinase domain (Stanton et al., 
1989). After the identification of the closely related isoforms ARAF and BRAF, 
research from many groups identified similar physiological roles of MEK and ERK, 
and eventually the field converged on a consensus view of the core RAS-ERK 
pathway (Lavoie and Therrien, 2015). 
KSR is the prototypical RAS-ERK scaffold. In addition to optimizing the 
proximity and orientation of RAS-ERK signaling modules, KSR can also prevent 
pathway crosstalk by anchoring or sequestering RAS-ERK modules from other 
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MAPK modules, preventing crosstalk (Ramos, 2008). The stoichiometry of scaffolds 
to MAPK modules also affects the ability of the pathway to signal. At too low of 
concentrations, the scaffolds fail to bring signaling components together and signaling 
is hindered. At too high of concentrations, MAPK modules bind different scaffolds 
and individually and again, signaling is impaired. Thus, cells can regulate the levels of 
scaffolds in order to tune ERK signaling. Indeed, KSR protein levels are regulated by 
the E3 ubiquitin ligase IMP1. While KSR is the most characterized scaffold, many 
others have been shows to bind RAS-ERK signaling modules which aids in context 
specific signaling.  
The N-terminal region of RAF contacts and inhibits the kinase domain in inactive 
RAF (Cutler et al., 1998; Rajakulendran et al., 2009). CRAF is also repressed by 
phosphorylation of S259 (BRAF has a homologous S365 site) by Akt and protein 
kinase A (PKA). When phosphorylated, these residues are bound by 14-3-3, holding 
RAF in an inactive conformation. When dephosphorylated by PP2A, 14-3-3 is 
released and RAF can become activated. Active GTP-bound RAS recruits RAF to the 
plasma membrane, binding to RAF’s RAS-binding domain. RAF then forms dimers 
with other RAF molecules, forming both homodimers and heterodimers. This 
dimerization is necessary for normal RAF function, as the BRAF-R509H mutation, 
located in the interface of the two RAF molecules, impedes both BRAF dimerization 
and activity (Rajakulendran et al., 2009). CRAF is then further activated by 
phosphorylation of S338 and Y441 (S299 on ARAF, S445 on BRAF) which is 
necessary for maximal RAF kinase activity for subsequent MEK binding (Lito et al., 
2013). In addition to these phosphorylations, RAF must also either homo-dimerize or 
hetero-dimerize in order to become fully signaling competent. 
However, S445 in BRAF is constitutively phosphorylated and together with a 
phosomimetic D445 (Y441 on CRAF) is thought to explain BRAF’s higher basal 
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activity. Phosphorylation of the activation loop is also required for RAF activity, 
though detection of these sites is technically difficult to detect through both 
phosphoproteomic and crystallographic techniques (Lavoie and Therrien, 2015). The 
net result is that BRAF is “charged” for activity, and requires only RAS-dependent 
recruitment to the plasma membrane, while ARAF and CRAF first require a 
constellation of phosphorylation events and plasma membrane recruitment in order to 
become signaling competent. 
The next step in the RAS-ERK cascade is the activation of the MAP-KK MEK1 
and MEK2 (Shaul and Seger, 2007). While the RAF isoforms are the best studied and 
most widely accepted MEK activators, there is evidence that several other MAPKKKs 
are capable of activating MEK, including COT (MAP3K8) (Caunt et al., 2015; 
Johannessen et al., 2010). While  MEK1 and MEK2 are 85% homologous. MEK must 
be recruited to RAF, either directly, or through scaffolding proteins like KSR1 and 
KSR2 (kinase suppressor of RAS, which resemble RAF but harbor inactivating 
mutations in their kinase domains) which are thought to recruit, orient, and stabilize 
the components of the RAS-ERK signaling module. RAF then phosphorylates the 
activation loop of MEK1 at S218 and MEK2 at S222, leading to their activation. 
While all three RAF family members have been shown to possess the capability to 
phosphorylate MEK, BRAF is the predominate isoform responsible for activing MEK. 
For instance, depleting normal brain of BRAF led to 96% reduction of MEK 
phosphorylation (Moodie et al., 1994). MEK is also phosphorylated at other residues 
to modulate its activity, including phosphorylation of S298 on MEK1 by p21-
activating kinase (PAK1) which increases activated MEK’s kinase activity. Although 
referred to collectively, MEK1 and MEK 2 have been shown to mediate specific and 
non-redundant roles in certain contexts (Skarpen et al., 2008). For instance, Mek2-/- 
19 
 
mice develop normally, while Mek1-/- mice results in embryonic lethality at E10.5 due 
to placental defects. 
Another class of scaffolds that deserves special mention as negative regulators of 
RAS-ERK signaling are the Raf kinase inhibitor proteins (RKIPs). RKIP binds RAF 
and MEK, but prevents their activation (Ramos, 2008). When RAS activates RAF, 
RKIP releases RAF and MEK, resulting in pathway activation. Consistent with 
activating the RAS-ERK pathway, RKIP is downregulated in various tumor types. 
MEK is a dual specificity kinase, and can phosphorylate both the tyrosine and 
threonine residues of its only validated substrate, the MAP-Kinase ERK. Indeed, 
MEK’s exquisite specificity for only ERK makes it a discriminatory gate in the RAS-
ERK pathway. In its inactive conformation, MEK binds inactive ERK, primarily 
retaining it in the cytoplasm. When activated, MEK phosphorylates and releases ERK. 
MEK activates ERK1 (also known as p44) at T202 and Y204 as well as and ERK2 
(p42) at T185 and Y187 (Roberts and Der, 2007). Upon dual phosphorylation, ERK’s 
serine/threonine kinase activity is activated, and ERK phosphorylates a whole host of 
substrates including transcription factors, other kinases and phosphatases cytoskeletal 
proteins, scaffolds, RTKs and intracellular signaling molecules, as well and many 
others. ERK is further phosphorylated on S244 and S246 (ERK2 numbering) are 
important for importin7 binding and nuclear translocation, although the specific kinase 
(or kinases) responsible for these sits have yet to be fully elucidated (Wainstein and 
Seger, 2016). Although referred to collectively, it is important to note that ERK1 and 
ERK2 are not entirely redundant, similar to MEK1 and MEK2. For instance, Erk2-/- 
mice  are embrypnic lethal by E8.5, while Erk1-/- mice are appear relatively normal 
(Ramos, 2008). 
ERK localization plays a substantial role in its regulation and activity. At rest, 
ERK is predominantly located in the cytoplasm bound to anchoring and scaffolding 
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proteins through its the common docking (CD) domain (Wainstein and Seger, 2016). 
When phosphorylated and activated, ERK is released and shuttled to other locations in 
the cell. Most activated ERK goes to the nucleus, but a portion also is shuttled to 
various organelles and membranes.   
Most recent estimates are that ERK has over 250 distinct substrates, split 
approximately equally between the nucleus and extra-nuclear locations (Wainstein and 
Seger, 2016). ERK phosphorylates many cytoplasmic substrates, but can also 
translocate into the nucleus where it can phosphorylate many other substrates, 
especially transcription factors (Shaul and Seger, 2007). Substrates of note include the 
transcription factors c-Fos and Elk1, which are activated by ERK phosphorylation, and 
drive proliferation, as do the vast majority of nuclear ERK substrates (Cargnello and 
Roux, 2011). Continuous ERK activity is also necessary and sufficient for Cyclin D1 
transcription, which is required to pass the restriction point and G1/S-phase 
checkpoint. Elk-1, and the ETS family ERK also amplifies its own signal by activating 
the family of kinases known as the MAPK-activated protein kinase (MAPKAPKs), 
including the cytoplasmic kinase p90RSK (Romeo et al., 2012). The RSK family of 
kinases phosphorylate their own diverse set of substrates that control proliferation, 
growth, migration, and survival. 
Just as important as the mechanisms of RAS-ERK pathway activation are the 
mechanisms by which the pathway is ultimately downregulated. As mentioned before, 
RAS is principally inactivated by GAPs which stimulate RAS’s intrinsic GTPase 
activity, hydrolyzing bound GTP to GDP and blocking RAS’s ability to bind to and 
activate its various effector pathways. One of the best studied RAS GTPases is the 
protein neurofibromin 1 (NF1). Interestingly, NF1 is commonly mutated or deleted in 
various cancer types, causing spurious RAS activation. 
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RAF, MEK, and ERK inactivation is firstly mediated by the dephosphorylation of 
the activating phosphoresidues by various phosphatases. On RAF, only the direct 
dephosphorylation of S338 by protein phosphatase 5 (PP%) has been described, but 
dephosphorylation of either site in MEK or ERK is sufficient to deactivate them 
(Lavoie and Therrien, 2015). There are several phosphatases that control the activity 
MAP kinase family members (MPKs, for MAP kinase phosphatases), and they are 
classified based on their preference for dephosphorylating tyrosine, serine/threonine, 
or both tyrosine and threonine (a family known as dual specificity phosphatases, or 
DUSPs) (Roskoski, 2012). 
Perhaps the most significant method of negative regulation in the RAS-ERK 
pathway is the negative feedback exerted by ERK across almost every component of 
the RAS-ERK in order to limit stimulation of the pathway under physiologic 
conditions (Lito et al., 2013). ERK phosphorylates EGFR at T669 in order to simulate 
receptor turnover. ERK (as well as p90RSK) also phosphorylate SOS1 on several 
sites, preventing ligand-bound RTKs from activating RAS. ERK also has recently 
been shown to phosphorylate NF1 which is thought to regulate its stability in response 
to growth factor stimulation. ERK also phosphorylates CRAF on many residues 
including S29, S43, S289, S96, S301, and S642 which act in concert to decrease 
CRAF kinase activity. Phosphorylation of S43 can also be carried about by PKA 
which hinders RAS-RAF association. ERK also phosphorylates MEK1 at T212 and 
T292 in order to inhibit its activity and prevent further activation by PAK1. 
In addition to its direct kinase activity, ERK also causes the transcriptional 
upregulation of many genes that, in turn, also inhibit activation of the RAS-ERK 
pathway. Active phospho-ERK directly induces the upregulation of the transcription 
of several DUSPs, which then dephosphorylate the tyrosine and threonine residues on 
ERK in order to deactivate it (Kidger and Keyse, 2016). There are three families of 
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DUSPs: DUSP1, DUSP2, DUSP4, and DUSP5 dephosphorylate nuclear ERK; 
DUSP3, DUSP7, and DUSP9 dephosphorylate cytoplasmic ERK; DUSP8, DUSP10, 
and DUSP16 act on other MAP kinases (like p38 and JUNK) instead of ERK, and not 
considered here any further. All of the DUSPs share a highly homologous structure of 
a non-catalytic and regulatory N-terminal domain and a catalytic C-terminal tail. 
Nuclear DUSPs contain a nuclear localization signal (NLS) while cytoplasmic DUSPs 
contain a nuclear export signal (NES). ERK has also been shown to phosphorylate 
DUSP1 which induces its degradation, underscoring the multi-layered and even 
reciprocal regulation of ERK and the DUSPs (Brondello et al., 1997) and perhaps 
helps determine the duration and intensity of ERK signaling following differing types 
and magnitudes of pathway activation. 
Dysregulation of the DUSPs is thought to play a role in many tumor types. 
DUSP6, the first ERK-selective DUSP to be identified is not mutated at any 
significant rate in any tumor type. However, in pancreatic tumors, of which 90% 
harbor activating RAS mutations, DUSP6 transcription was consistently lowered, 
often through epigenetic silencing of the DUSP6 promoter (Furukawa et al., 2003). 
Furthermore, in lung cancer, about 17% of tumors surveyed demonstrated loss of 
heterozygosity at the DUSP6 locus and a concomitant decrease in DUSP6 expression, 
underscoring the important escaping (or disabling) the physiological pressure of 
ERK’s own negative feedback (Okudela et al., 2009).  
Another class of inducible negative regulators of the RAS-ERK pathway are the 
Sprouty family of genes (SPRY). SPRY proteins are phosphorylated on an N-terminal 
tyrosine which can serve as a docking site for GRB2 (through its SH2 domain), 
thereby sequestering GRB2 away from SOS and RTKs at the cell membrane 
(Hanafusa et al., 2002; Lito et al., 2013). Furthermore, mutations in the protein 
SPRED (transcriptionally upregulated by ERK) which is also a member of the SPRY 
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family, have been shown to prevent NF1 from associating with RAS at the cell 
membrane (Stowe et al., 2012). These mutations were found in patients with a RAS-
opathy, a collection syndromes associated with overactive RAS-ERK signaling.  
With an understanding of the negative feedback and feed-forward mechanisms in 
the RAS-ERK pathway, it helps to consider the example of pathway activation in the 
context of PC12 cells again. By modulating individual components of the RAS-ERK 
pathway with RNAi such as ERK’s DUSP or MEK’s phosphatase, Santos et al. 
observed that EGF stimulation resulted in only negative feedback and therefore 
transient ERK activation (Santos et al., 2007). Conversely, following NGF 
stimulation, ERK output was sustained and only positive, reinforcing feedback was 
observed to CRAF via protein kinase C (PKC). By activating PKC with phorbol-12-
myristate-13-acetate (PMA) in conjunction with EGF, the authors achieved sustained 
ERK activation resembling NGF activation. This demonstrates that altering levels of 
feedback proteins and their activity can alter systems level ERK activity.  
 
 
Part 4 – RAS-ERK signaling in cancer 
 
While dysregulation of RAS-ERK signaling had been noted for a long time in the 
cancer research community, the landmark finding in 2002 by Davies et al. described 
mutations in BRAF in several different tumor types (Davies et al., 2002). Using a 
panel of cell lines, most with matched normal blood for comparison, the group noted 
mutations in BRAF in “59% [of] melanomas, 18% [of] colorectal cancers, 11% [of]  
gliomas, 3% [of] lung cancers, 9% [of]  sarcomas, 4% [of] ovarian carcinomas, 2% 
[of]  breast cancers and 14% [of]  liver cancers,” establishing recurrent somatic 
mutation of BRAF. Interestingly, the authors noted that the cancer types in which 
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BRAF mutations most frequently occurred were also types which frequently harbored 
mutations in the RAS genes, underscoring the important of the RAS-ERK pathway to 
these cancer types. Of the tumor types surveyed with BRAF mutations, 89% harbored 
a mutation within the activation loop of BRAF. Of those, 92% were a single amino 
acid substitution at valine 600, most often to glutamic acid (V600E) and less 
frequently to several other amino acids.  
Since 2002, numerous genome-wide sequencing studies, including those done 
through the TCGA project, have established the rate of BRAF mutation at around 50-
60% in malignant melanoma, 30-50% in thyroid, 10% in colorectal, 100% on hairy 
cell leukemia, and about 3% in lung and glioma each (Samatar and Poulikakos, 2014). 
Indeed, most recent counts find that nearly all mutations in BRAF occur in the kinase 
domain, 98.4% occur at V600 (of which 97.8% are V600E) (Lavoie and Therrien, 
2015). Genome-wide surveys have identified very few mutations in CRAF, and even 
fewer in ARAF, KSR1, and KSR2, of whose importance has very to be identified in 
any significant manner (Forbes et al., 2011). 
After identifying the recurrent mutations in BRAF, Davies et al. expressed cDNAs 
for BRAF harboring the various mutations they had observed in order to ascertain 
their oncogenic potential (Davies et al., 2002). BRAF-V600E had a much higher 
elevated in vitro kinase rate than wild-type BRAF and was also able to induce 
transformation of NIH-3T3 cells. Confirmation of the oncogenic role of BRAF-V600E 
came from the introduction of BRAF-V600E alleles into transgenic animals. Mice and 
zebrafish with a BRAF-V600E allele expressed in a melanocyte tissue-specific 
manner displayed senescent melanocytic masses as well as highly invasive tumors 
(Mercer et al., 2005; Patton et al., 2005). Indeed, mutations in BRAF have also been 
identified in many RAS-opathies (Rauen, 2013). These patients also often display a 
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predisposition to various malignancies as well, underscoring the role mutations in 
BRAF play in pathogenic RAS-ERK signaling. 
The mechanistic and oncogenic role of BRAF in cancer derives from two 
important observations. The first is that BRAF is “primed” to signal. Recall that 
ARAF and CRAF require five different phosphorylations in order to become 
completely signaling competent, while BRAF only has four of these conserved sites 
and has a phosphomimetic aspartic acid at CRAF-Y341/BRAF-D448 (Wellbrock et 
al., 2004). Moreover, the CRAF-S338/BRAF-S445 site is constitutively 
phosphorylated in BRAF. This “priming” shows while a single amino acid substitution 
is sufficient for oncogenic activation, while CRAF and ARAF would require several  
more activating mutations, and likely explaining their relative scarcity in cancer. 
The second important observation derives from a crystallographic model of wild 
type BRAF and BRAF-V600E bound with a first generation RAF inhibitor (Wan et 
al., 2004). From this model which assumes that inhibitor-bound BRAF mimics ATP-
bound BRAF, mutations in the activation segment of BRAF (for example, BRAF-
V600E) destabilize the hydophobic interactions of valine 600 with the phenyl 468 
which hold it in an inactive conformation. Substituting valine 600 with a larger and 
charged side chain breaks the interaction, frees the activation loops and eliminates the 
need for its phosphorylation, and allows BRAF to fold into an active conformation. 
Other models propose that hydrophobic interactions between the G-loop and the DFG 
motif/P-loop of the activation segment are primarily responsible for holding BRAF in 
an inactive conformation (Lito et al., 2013).  
As mentioned previously, RAF signaling requires hetero- or homo-dimerization in 
order to become fully signaling competent (Cutler et al., 1998; Rajakulendran et al., 
2009). The BRAF-R509H mutation prevents the dimerization of BRAF, and 
attenuates the growth advantage in RAS-mutant cells (Hatzivassiliou et al., 2010). 
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Furthermore, the p61-BRAF mutation results in the loss of exons 4-8 of BRAF, 
leading to the constitutive dimerization of BRAF, even in the absence of activated 
RAS-GTP, and its oncogenic signaling to ERK (Poulikakos et al., 2011).  
Following the discovery and conformation of the role of BRAF-V600E across 
many types of cancer, it was proposed that as a kinase, BRAF might be a druggable 
therapeutic target using ATP-competitive compounds (Tuveson et al., 2003). For 
instance, conditional expression and ablation of a BRAF-V600E allele with an shRNA 
resulted in inducible growth and regression of melanoma models (Hoeflich et al., 
2006). The most pivotal evidence for the therapeutic potential of inhibiting mutant-
BRAF was the discovery the BRAF-V600E oncogene in diverse tissue types was 
highly predictive of sensitivity to MEK inhibitors relative to RAS-mutant cell (whose 
sensitivey to MEK inhibition was more varied) or wild-type cells (Solit et al., 2006). 
Indeed, there was much pharmaceutical interest in developing CRAF inhibitors 
initially, primarily based on their role as RAS effectors, including the development 
and approval of the drug sorafenib. Sorafenib’s approval was based on its efficacy in 
renal and liver cancers, and considering the relative lack of RAS-ERK mutations in 
these tumor types, the current consensus is that sorafenib’s efficacy is largely derived 
from its “off-target” inhibition of vascular endothelial growth factor receptor 
(VEGFR) family kinases (Bollag et al., 2012). Indeed, sorafenib was relatively 
ineffective in melanoma trials with unselected patient populations, which is 
unsurprising considering that sorafenib preferentially inhibits CRAF and only weakly 
binds mutant-BRAF.  
The first mutant-BRAF selective inhibitor to receive FDA approval was 
vemurafenib (PLX4032, Zelboraf; Genentech/Plexxikon) in 2011 (Bollag et al., 2010, 
2012; Tsai et al., 2008). Vemurafenib was propelled through the approval process by 
its striking response rate in mutant-BRAF selected patients with a “confirmed best 
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overall response rate of >50% and median progression-free survival of approximately 
7 months” in Phase I and II trials comparted to a historical response rate to 
decarbazine, a cytotoxic chemotherapeutic agent, of <10% and 2 months (Bollag et al., 
2012; Flaherty et al., 2010; Sosman et al., 2012). In fact, vemurafenib showed such 
promise in its Phase I and II trials that the FDA instructed that exposure to the control 
arm should be minimized out of ethical concerns (Chapman et al., 2011). Vemurafenib 
was approved in less than 5 years, an almost unheard of period in oncology (Bollag et 
al., 2012). 
In biochemical assays, vemurafenib had a slightly higher affinity to mutant BRAF 
over wild type BRAF. However, in call-based assay, vemurafenib inhibited ERK 
signaling and associated proliferation in a highly BRAF-V00E selective manner, and 
demonstrated no effect in RAS-driven tumors (Joseph et al., 2010). This was initially a 
curious result considering that RAF is a key effector of RAS-ERK signaling. Several 
landmark works elucidated the mechanisms for these observations. The first evidence 
in 1999 was that an early CRAF inhibitor seemed to fail to block ERK 
phosphorylation despite being an effective inhibitor in in vitro studies (Hall-Jackson et 
al., 1999). This observation was underappreciated at the time though due to the lack of 
a market for RAF inhibitors. Another piece of evidence was the understanding of 
RAS-RAF signaling dynamics, and the observation that RAS-driven RAF dimer 
formation is required under physiological conditions in order for RAF to signal to 
ERK (Rajakulendran et al., 2009).  
A further curious result was the occurrence of benign, but debilitating cutaneous 
squamous-cell carcinomas and keratoacanthomas in 15-30% of patients treated with 
first generation RAF inhibitors. Another landmark paper showed that the tumors in 
these patients harbored activating RAS mutations in approximate 60% of cases (Su et 
al., 2012). This finding initially worried the field, fearing that either vemurafenib or 
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RAF inhibition in general might be carcinogenic. This worry was dispelled by elegant 
studies that showed that kinase dead BRAF (kd-BRAF) cooperates with mutant-RAS 
in the presence of a RAF inhibitor to drive kd-BRAF/CRAF dimer formation, CRAF 
activation, and ultimately signaling to ERK, demonstrating that RAF pathway 
inhibition itself was not the cause of the secondary tumor formation (Heidorn et al., 
2010). 
These results finally coalesced around a unified view of RAF inhibitors in a pair of 
papers published in Nature by a team of scientists at Genetech (Hatzivassiliou et al., 
2010) and the Rosen lab at the Memorial Sloan Kettering Cancer Center (Poulikakos 
et al., 2010). Hatzivassiliou et al measured the sensitivity of a panel of BRAF-V600E, 
RAS-mutant, and RAS/RAF-wild type cell lines to ATP competitive RAF inhibitors 
and MEK inhibitors (Hatzivassiliou et al., 2010). While all of the cell lines were quite 
sensitive to the MEK inhibitor PD0325901 (PD-901), only the BRAF-V600E cells 
lines demonstrated an exquisite sensitivity to the RAF inhibitors, including 
vemurafenib, while the RAS-mutant and RAS/RAF-wild type cell lines were all 
insensitive. They further demonstrated that in the context of mutant-RAS, RAF 
inhibitor binding to RAF results in the formation of RAS-dependent BRAF-CRAF 
dimers, membrane localization, and interaction with RAS-GTP.  
Poulikakos et al. started with a very similar observation: while ATP-competitive 
RAF kinase inhibitors indeed block ERK phosphorylation in mutant-BRAF contexts, 
they paradoxically stimulate ERK signaling above baseline in BRAF-wildtype/RAS-
mutant contexts that eventually becomes inhibited at much higher drug concentrations 
(Poulikakos et al., 2010). Using elegant chemical genetic experiments, Poulikakos 
demonstrated that vemurafenib binding to the ATP site of one protomer of a BRAF-
BRAF or BRAF-CRAF dimer inhibits that promoter and then transactivates the other 
promoter in the presense of mutant-RAS, though the effect was much more significant 
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in CRAF containing dimers. In both studies though, so-called BRAF inhibitors failed 
to inhibit wild-type BRAF or CRAF. Also, in the presence of high-levels of RAS-GTP 
(induced through expression of a mutant-RAS allele), vemurafenib failed to inhibit 
BRAF-V600E signaling, though in both cases signaling was sensitive to a MEK 
inhibitor. These observations also showed significant clinical meaning. While RAF 
inhibitors would be expected to inhibit RAF-ERK signaling in tumor cells with 
BRAF-V600E, they would not in normal cells in the rest of a patient’s body (or they 
would induce signaling, causing the cutaneous squamous-cell carcinomas and 
keratoacanthomas observed in some patients), suggesting that RAF inhibitors would 
have a much wider therapeutic index than would MEK inhibitors, which would inhibit 
MEK across all tissues in a patient. This would allow RAF inhibitors to be 
administered at high doses and more durably suppress ERK signaling. Indeed, 
complete suppression of ERK signaling is necessary to receive full therapeutic benefit 
from any drug designed to inhibit ERK signaling (Bollag et al., 2010). Because of the 
broad tissue activity of MEK inhibitors, administration of these drugs is often limited 
by their toxicities, leading to lower observed clinical efficacy.  
The Rosen lab further showed that while RTK-activated tumors and BRAF-V600E 
tumors both demonstrate similar levels of activated ERK, only the BRAF-V600E cells 
were dependent on that ERK signaling (Pratilas et al., 2009). Indeed, using gene 
expression arrays, the group demonstrated that feedback inhibition in RTK-activated 
tumors attenuated ERK output (as measured by transcriptional output of ERK-
dependent genes) while BRAF-V600E tumors appeared to be insensitive, ad in fact, 
appeared to be able to evade ERK-dependent feedback inhibition.  
How RAF was able to evade this ERK dependent feedback then became an area of 
intense study. While observing RAF mutations that were acquired during vemurafenib 
treatment, Poulikakos found a BRAF mutant with an in-frame deletion of exons 4-8, 
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termed p61-BRAF-V600E (Poulikakos et al., 2011). While this truncated BRAF 
isoform was insensitive to vemurafenib, p61-BRAF-V600E which was engineered to 
co-express the dimer-breaking R509H mutant (p61-BRAF-V600E/R509H) rendered 
the mutant sensitive to vemurafenib, underscoring the importance of BRAF monomers 
to RAF inhibitiors.  
One more important finding about ATP-competitive RAF inhibitors also came 
from the Rosen lab. Yao et al. used the ATP competitive RAF inhibitor LGX818, 
which has as extremely low pharmacokinetic off-rate and remains bound to RAF even 
after washing, to demonstrate that cells expressing mutant-RAS required much higher 
concentrations of first generation RAF inhibitors to bind the second protomer of RAF 
dimers that was required for the first protomer, establishing that RAF dimers 
demonstrate a negative cooperativity in addition to their RAS-dependent transactivity 
(Yao et al., 2015b). This phenomenon was irrespective of the RAF inhibitor used. 
Lito et al. showed in a later study that negative feedback from active ERK to the 
RTKs themselves, as well as their signaling apparatus (SOS, Grb2, loss of Sprouty and 
DUSPs) indeed suppressed RTK signaling upstream of BRAF-V600E, leading to low 
RAS-GTP levels (Lito et al., 2012). Without sufficient levels of RAS-GTP, RAF fails 
to form dimers. However, BRAF-V600E signals effectively as a monomer, allowing it 
to evade the powerful feedback of its oncogenic signaling. Lito further showed that 
following long term vemurafenib treatment, RAS-GTP levels became slightly 
elevated, presumably leading to the formation of RAF-inhibitor insensitive dimers.  
The source of this RAS-activation is hypothesized to come from various sources. 
Perhaps the primary driver is the loss of feedback inhibition of RTK components 
(SPRY2, SOS) (Lito et al., 2012). One hypothesized observation of would be that 
RTK-ligand stimulation of non-RAF inhibitor treated cells would activate their 
cognate receptors, but fail to activate downstream signaling. Indeed, non-vemurafenib 
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treated melanoma cells when treated with EFGF or NRG-1 activated EGFR and HER2 
respectively, but failed to induce downstream signaling. Treatment with vemurafenib 
relieved the negative feedback on these receptors and restored their ability to signal.  
Secondly, stromal secretion of RTK ligands has also been implicated in resistance 
to RAF inhibitor treatment. In a pair of papers co-published in Nature in 2012, two 
groups demonstrated that ligand secretion of hepatocyte growth factor (HGF) and the 
activation of its receptor MET led to RAF inhibitor resistance (Straussman et al., 
2012; Wilson et al., 2012). While not directly demonstrated in the papers, presumably 
RTK activation would lead to RAS activation and an increase in RAS-GTP. Indeed, a 
similar secrotome experiment by Lito et al. confirmed the ability of secreted ligands to 
attenuate the effect of RAF inhibitors (Lito et al., 2012). Considering these papers 
together though, ligand secretion alone would likely be necessary, but not sufficient, to 
induce RAF inhibitor resistance (Lito et al., 2012). Resistance would also require RAF 
inhibitor treatment itself in order to relieve negative feedback on the RTK signaling 
apparatus in order to restore “signalability” to the ligand activated receptors. 
Another mechanism of RAS-GTP level elevation comes from ERK-dependent 
transcriptional activity. Treatment with vemurafenib has also been shown to relieve 
active ERK-dependent repression of RTK ligand transcriptions. For example, when 
mutant-BRAF thyroid cells were treated with vemurafenib, transcription and autocrine 
secretion of the HER3 ligand neuregulin-1 (NRG1) was observed along with the 
activation of its receptor (Montero-Conde et al., 2013). 
Ultimately, these observations were synthesized into what became known as the 
“RAF inhibitor paradox” (Samatar and Poulikakos, 2014). While first generation RAF 
inhibitors showed relatively similar in vitro potencies to various RAF isoforms, in 
vivo they inhibit ERK signaling in a strictly BRAF-V600E-dependent manner, and in 
fact stimulate ERK signaling in RAS-mutant cells. This is due to active RAS-
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dependent RAF-dimerization, in which context RAF inhibitors transactivate the non-
drug bound protomer and induce a negative cooperativity that limits the ability of the 
drug to inhibit its target effectively. Indeed, any context which induces RAF 
dimerization—for example, RAS activation (Hatzivassiliou et al., 2010; Poulikakos et 
al., 2010), N-terminal regulatory truncations of RAF (Poulikakos et al., 2011; Stanton 
et al., 1989)—would be expected to lead to RAF inhibitor insensitivity. 
Indeed, this can be further contextualized into a view of tumor adaption to RAF 
inhibitor resistance (Lito et al., 2013). Initially low levels of RAS-GTP in BRAF-
V600E mutant cells are due to the strong negative feedback of the constitutively high 
levels of activated ERK on RTKs, their signaling adaptor proteins (SPRY proteins, 
GRB2 and SOS phosphorylation), and on the MEK and ERK itself (including direct 
inhibitory phosphorylations and expression of DUSPs). This feedback inhibition 
prevents the signaling of RTKs, even in the presence of their activated ligands. The 
feedback also means that BRAF-V600E exists predominantly as a monomer that is 
sensitive to vemurafenib. Following RAF inhibitor treatment, RAF is inhibited along 
with ERK signaling, leading to a loss of feedback inhibition. RTKs in cells in this 
state can then be stimulated by ligands, leading to a strong increase in RAS-GTP 
levels. Elevated RAS-GTP levels lead to RAF dimerization and loss of RAF inhibitor 
binding. This leads to an increase in ERK signaling, restoring some amount ERK-
dependent feedback. The cells will eventually reach a new steady state with both 
RTK-ligand sensitivity, some ERK activity, and relatively low drug sensitivity. 
 While most of the discussion to this point has been of BRAF-V600E in the 
context of melanoma, as mentioned earlier, BRAF-V600E mutations are also found in 
many other tumor types. However, in striking contrast to melanoma, RAF inhibition 
appears to be far less effective is most other tumor types. Indeed, a recent basket trial 
which enrolled all patients with BRAF-V600 mutations in various non-melanoma 
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cancer types demonstrated heterogeneous responses to vemurafenib treatment (Hyman 
et al., 2015). In BRAF-V600 non-small cell lung cancer (NSCLC), objective responses 
were observed in 40% of patients while no (0%) of responses were observed in a 
cohort of colorectal cancer (CRC) patients. 
The relative insensitivity of BRAF-V600E positive CRC has been an area of 
intense study since shortly after the discovery of BRAF mutations. Approximately 
10% of CRC patients harbor a BRAF alteration (Cancer Genome Atlas Network, 
2012). Whereas BRAF-V600E positive melanoma patients demonstrate an almost 
50% partial response rate to vemurafenib (Chapman et al., 2011), only 5 of 19 BRAF-
V600E positive colorectal cancer (CRC) patients demonstrated a partial response in a 
Phase I trial (Kopetz et al., 2010). Indeed, patients with mutant-BRAF positive tumors 
exhibited a 70% increase in mortality over those with wild type BRAF (Van Cutsem et 
al., 2011). 
 Preclinical evaluation of BRAF-V600E CRC models demonstrated that 
vemurafenib could be added to several different approved treatment modalities, 
including the chemotherapies capecitabine and irinotecan, the anti-angiogenic 
antibody bevacizumab, or EGFR inhibitors cetuximab and erlotinib, to various 
amounts of positive benefit(Yang et al., 2012), but no mechanistic basis for these 
observations were uncovered.  
Two studies in 2012 implicated EGFR as a key mediator of resistance to 
vemurafenib in CRC (Corcoran et al., 2012; Prahallad et al., 2012). A key observation 
is that while vemurafenib is able to durably suppress most ERK activation in the 
context of melanoma with only minimal tumor adaptation (Lito et al., 2013), ERK 
inhibition is only transient in CRC and quickly rebounds with 24 to 48 hours to 25-
50% of original levels (Corcoran et al., 2012). Corcoran et al. also observed that 
vemurafenib relieved negative feedback on EGFR in CRC cell lines, leading to an 
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increase in RAS-GTP and RAF dimer formation, leading to relative vemurafenib 
insensitivity (Corcoran et al., 2012). Treating cells with an EGFR inhibitor with 
vemurafenib abrogated the increase in RAS-GTP and prevented the rebound in 
activated ERK. Similarly, Prahallad et al. observed that loss of ERK activity also 
results in a loss of CDC25C activity, a phosphatase responsible for dephosphorylating 
and deactivating EGFR, potentially leading to aberrantly activated EGFR (Prahallad et 
al., 2012). 
BRAF is also commonly mutated in papillary thyroid carcinomas (Cancer Genome 
Atlas Research Network, 2014). In the thyroid context, vemurafenib was also unable 
to durable suppress ERK signaling. The mechanism observed in thyroid cancers was 
that loss of ERK negative feedback led to a depression of neuregulin-1 (NRG1) 
expression, a ligand that specifically activates the RTK HER3, as well as HER3 total 
receptor levels (Montero-Conde et al., 2013). This potent combination of permissive 
RTK signaling again leads to RAF dimerization and vemurafenib insensitivity.  
In both of these cases, it is important to note that before vemurafenib treatment, 
ERK activity is insensitive to negative feedback and is largely only under the control 
of mutant-BRAF. Following drug treatment with vemurafenib, ERK activity then 
becomes dependent not only on mutant-BRAF but also on RTKs, RAS-GTP levels, 
and the induction of RAF dimers. 
 
Part 5 – Drugs targeting the RAS-ERK pathway 
 
The landscape of RAF inhibitors in preclinical development are quickly 
diversifying, though only two, vemurafenib and dabrafenib (Tafinlar; GSK)(Hauschild 
et al., 2012), are FDA approved in the setting of metastatic melanoma with BRAF-
V600 mutations. Vemurafenib and dabrafenib and structurally distinct from one other, 
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but both are ATP-competitive and have similar pharmacodynamic profiles in that they 
induce paradoxical activation (via induced dimerization and transactivation) (Uehling 
and Harris, 2015). Many other RAF inhibitors are in clinical and preclinical 
development. Encorafenib (LGX818, Novartis/Array) binds in a similar manner as 
vemurafenib and dabrafenib but is possibly the most selective of the RAF inhibitiors 
described to date and also binds much more tightly with a disassociation half-life of 
over 24-hours (Uehling and Harris, 2015). Encorafenib still displays similar 
paradoxical activation, though its side-effect profile shows that it might be better 
tolerated due to the lower doses required.  
Together, these drugs are “first-generation” RAF inhibitors that derive most of 
their clinical benefit in the BRAF-V600 contexts as they activate ERK signaling in the 
BRAF-wild type setting. A newer generation of drugs have been designed to avoid 
paradoxical activation (Arora et al., 2015). This class of drugs has been termed 
“paradox breakers.” Several of these paradox breaking drugs have recently been 
introduced, and some have even entered into clinical trials (Uehling and Harris, 2015). 
One of the best described of these BRAF-mutant selective paradox breakers is 
PLX8394 (Plexxikon) (Zhang et al., 2015) in that it demonstrates some selectivity for 
mutant-BRAF over wild type RAF alleles, is able to inhibit mutant-BRAF signaling, 
yet ultimately fails to induce RAF signaling in the RAS-mutant/RAF wildtype context. 
Of note in glioma, a preclinical version of PLX8934 (PLX PB-3) was able to inhibit a 
constitutively active BRAF dimer where the N-terminal regulatory region of BRAF is 
translocated in frame with a portion of the KIAA1549 gene (known as 
BRAF:KIAA1549) (Sievert et al., 2013). This fusion was shown to constitutively 
dimerize, which would be expected to make it insensitive to vemurafenib, which was 
demonstrated. However, PLX PB-3 was able to inhibit fusion BRAF signaling while 
vemurafenib paradoxically activated it. Another of these compounds is PLX7904 
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(Plexxikon) which failed to elicit ERK activation is RAS-mutant/RAF wildtype cells 
and was also shown to inhibit mutant-BRAF in melanoma cells that were resistant to 
vemurafenib due to acquiring a mutant NRAS allele, leading to RAS activation and 
RAF dimerization (Le et al., 2013). The drug failed to inhibit ERK activation in the 
NRAS-mutant/RAF-wildtype setting however. The observation the PLX7904 is able 
to inhibit the growth of NRAS-mutant/BRAF-mutant cells but not NRAS-
mutant/RAF-wildtype suggests that the drug binds to mutant-RAF in mutant-
BRAF/CRAF dimers, inhibits the mutant-BRAF protomer, but most importantly, fails 
to transactivate the CRAF protomer. 
The drug TAK-632 (Takeda) (Nakamura et al., 2013) showed reduced paradoxical 
activation relative to vemurafenib. At low concentrations TAK-632 modestly induced 
MEK and ERK activation, but as the concentration increased, the drug inducted the 
formation of BRAF/CRAF heterodimers, but completely inhibited RAF kinase activity 
(as measured by MEK and ERK activation). The drug also demonstrated a very low 
off rate and remained bound which is the most likely reason for durable dimer 
inhibition. 
The drug BGB-659 (Beigene, Millennium Pharmaceuticals) is another such 
paradox breaker (Gould et al., 2011). The drug binds both sites of BRAF dimers with 
similar affinities. BGB-659 inhibits mutant-BRAF signaling from V600E monomers 
and dimers (p61-BRAF-V600E) at similar concentrations (Yao et al., 2015b). In 
addition, the drug has paradoxical activating activity in the wild-type RAF and wild-
type RAS context, which suggests that the drug should inhibit mutant BRAF signaling 
while sparing wild-type RAF signaling in other tissues of the body, widening its 
therapeutic window.  
Some newer drugs are the pan-RAF inhibitors. These drugs are potent towards all 
RAF isoforms (ARAF, BRAF, and CRAF), including both mutant (V600) and wild-
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type. The recently described drug LY3009120 is one such compound (Peng et al., 
2015). Similar to TAK-632, LY3009120 induces both BRAF/CRAF 
heterodimerization and BRAF/BRAF homodimerization, yet effectively inhibits RAF 
kinase activity. LY3009120 also inhibits ERK signaling in RAS-mutant cells (0.384-
1.17 μM), though at higher concentrations than what is required in mutant-BRAF cells 
(0.010-0.446 μM).  Consistent with an ability to block RAF signaling in a RAS-
mutant context, these drugs would be expected to have a narrower therapeutic window 
than vemurafenib or BGB-659 though they are tolerated in vivo and are able to induce 
tumor regression in both BRAF-V600E and KRAS mutant xenograft models. 
 
Part 6 – BRAF mutations in tumor types other than melanoma 
 
Although much research has been conducted to understand BRAF mutations in 
melanoma, CRC, and thyroid tumors, less is known about how BRAF mutations 
function in glioma. While about 3% of Grade IV GBM harbor the canonical BRAF-
V600E mutation, other gliomas have different BRAF mutations. In low grade gliomas 
(especially pilocytic astrocytoma,) BRAF fusions, including the BRAF:KIAA1549 
fusion are a defining hallmark genetic lesion (Sievert et al., 2013). In these fusions, the 
N-terminal region of BRAF (and sometimes CRAF) is lost, leading to the constitutive 
dimerization and kinase activity. Indeed, these RAF fusions have been demonstrated 
to undergo paradoxical activation by vemurafenib. 
Less is known about the sensitivity of BRAF-V600E mutations in glioma. Work 
by the James group have shown in preclinical experiments that these tumors are 
dependent on BRAF for proliferation using short-hairpins to known down BRAF 
expression (Nicolaides et al., 2011). Also, vemurafenib can inhibit mutant BRAF 
signaling in the cells as well. Indeed, vemurafenib extended survival in mice bearing 
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intracranial xenografts of BRAF-V600E glioma cell lines by approximately a week 
(median survival was extended from 20 days in vehicle treated mice to 27 in 
vemurafenib treated mice). 
The James group has also explored if combining vemurafenib with other treatment 
regiments might be able to augment their efficacy. Indeed, they showed that BRAF 
mutations cooperate with CDKN2A loss to induce the formation of high grade gliomas 
in transgenic mouse models (Huillard et al., 2012), consistent with reports that 
constitutively active alleles of BRAF alone tend to cause oncogene induced 
senescence and require a second mutation for oncogenic bypass (Michaloglou et al., 
2005). These tumors also responded to both BRAF inhibition with vemurafenib and 
CDK4/6 inhibition with PD-0332991 as monotherapies. Combination therapy 
provided an additive (as opposed to a synergistic) effect. An additive positive benefit 
has also been observed when BRAF-mutant gliomas were treated with radiation and a 
low dose of vemurafenib, although the group failed to establish a mechanistic basis 
(Dasgupta et al., 2015). 
Although the evidence that vemurafenib treatment is beneficial in BRAF-mutant 
glioma seems to be relatively well established, its efficacy in comparison to other 
BRAF-mutant tumors is less well understood. A survey of case reports in all types of 
gliomas with BRAF-V600E mutations has found that of 28 cases of various histology, 
most patients at best achieved stable disease or a partial response (Preusser et al., 
2016). In a basket trial which enrolled patients with non-melanoma tumors with 
BRAF-V600E mutations, a similarly varied response was observed, with two of five 
patients progressing, and two of five achieving a partial response (Hyman et al., 2015). 
Why exactly BRAF-V600E gliomas seem to be relatively insensitive to BRAF 
inhibitors is also relatively not well known. The James group has suggested that EGFR 
becomes feedback reactivated following BRAF inhibition though ERK-mediated loss 
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of expression of the EGFR inhibiting phosphatase PTPN9 (Yao et al., 2015a), 
ultimately preventing durable pathway suppression. This would be consistent with the 
mechanisms observed in CRC and thyroid tumors (Corcoran et al., 2012; Montero-
Conde et al., 2013; Prahallad et al., 2012). While the president for such a mechanism 
existing in glioma is possible, the data the group presented are inconclusive. While 
neratinib (also known as HKI-272) is a potent EGFR inhibitor, it also inhibits the 
entire ERBB family of proteins, as well as a whole suite of other kinases (Fabian et al., 
2005). While the in vivo data showed a 10% increase in the median survival time over 
either drug as a monotherapy, most of the other data the presented fail to demonstrate 
an additive effect between the drugs beyond the efficacy of each drug as a mono-
therapy. Indeed, neratinib alone as a monotherapy shows efficacy in most of their 
assays, despite the fact that the authors’ model posits that EGFR must be feedback 
reactivated by vemurafenib first. 
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CHAPTER 2: BRAF-V600E GLIOMA IS GENETICALLY DEPENDENT ON 
MUTANT BRAF 
 
Introduction 
  
 Traditionally cancer patients in the clinic have received very similar treatments 
for their tumors. These treatments, like ionizing radiation and cytotoxic chemotherapy, 
are usually very toxic. However, following the advent of high throughput DNA 
sequencing in recent years, determining which genes are mutated in a given patient’s 
tumor has become more routine. This information has begun to inform decisions as to 
which treatments parents might benefit from based on the specific mutations found 
within their tumors. 
 Gliomas, a general term for tumors of the central nervous system, account for a 
disproportionate amount of morbidity and mortality, despite being relatively more 
uncommon that other tumor types. However, few treatments available for glioma 
patients, who are typically treated with bulk surgical resection, radiation, and 
chemotherapy. However, if clinicians knew more about which mutations these 
patients’ tumors harbored, they might be able to use more effective and less toxic 
tailored drugs. 
For instance, various mutations found in human cancer can activate the RAS-
RAF-MEK-ERK (RAS-ERK) signaling pathway, and there are several drugs designed 
to inhibit oncogenic RAS-ERK signaling. The RAS family of genes are the most 
commonly mutated in all cancers, found in approximately one-third of all tumors 
(Samatar and Poulikakos, 2014). However, while mutations in RAS do occur in 
glioblastoma (GBM), they are vanishingly rare (Knobbe et al., 2004).  
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While RAS activates the protein RAF, activating mutations in the BRAF gene 
are also found in approximately 8% of all tumors. These mutations are most common 
in melanoma where they make up approximately 50% of sequenced tumors. BRAF-
mutant melanoma is highly addicted to mutant-BRAF signaling to MEK and ERK 
(Samatar et al.,, 2012). Specific inhibitors of MEK and ERK signaling in BRAF-
mutant melanoma result in profound responses, leading to dramatic tumor shrinkage. 
Several reports that surveyed the frequency of RAF mutations in gliomas have 
suggested that BRAF is recurrently mutated (Horbinski 2014). The frequency of these 
mutations varies based of the histology of the tumor type. Therefore, we sought to 
verify the frequency of BRAF alterations in gliomas and determine if they are 
similarly dependent on mutant-BRAF signaling like in melanoma.  
 
Results  
 
 We initially sought to verify and summarize the frequency of BRAF alterations 
in gliomas based on databases of mutations in gliomas whose DNA has been 
sequenced. 
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Figure 2-1. Frequency of BRAF alterations in adult human glioma. Shown is the 
frequency of human glioma samples harboring a BRAF missense mutations, 
fusion, or gene amplifications. (A)  Frequency of BRAF-V600E and 
BRAF:KIAA1549 fusions as compiled by Horbinski C, J Neuropathol Exp Neurol. 
2013. (B) The numbers are from two different datasets. The Cancer Genome Atlas 
(TCGA) only includes patients with glioblatoma (WHO grade IV), whereas the 
MSKCC in-house sequencing database (IMPACT) includes glioblastoma and lower 
grade (WHO grade II/III) gliomas.  B-K – BRAF:KIAA1549; PA - pilocytic 
astrocytoma; PMA - pilomyxoid astrocytoma; PXA - pleomorphic xanthoastrocytoma; 
GG - ganglioglioma; DA - grade II diffuse astrocytoma; HGG = high-grade glioma 
(grade III and IV). 
 
 We first looked at a literature review of BRAF mutations in gliomas (Figure 2-
1A). Horbinski complied the total frequency of BRAF-V600E mutations from various 
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references as of 2013, comprising over 700 tumors of various histologies (Horbinski, 
2013). In these tumors, BRAF-V600E mutations were found most frequently in PXA 
(~74%), GG (~20%), and HGG (~13%). BRAF:KIAA1549 fusions were most 
commonly found in PA (~66%) and PMA (~50%). Interestingly, thiese BRAF fusions 
were never found in HGG. They were exclusively confined to lower grade tumors. 
Because literature resources can over-report the frequency of mutations, we 
looked at a more unbiased approach to determining the frequencies of BRAF 
alterations.  To do so, we analyzed the results of the IMPACT database (Figure 2-1B). 
Tumors from patients treated at Memorial Sloan Kettering are submitted for IMPACT 
testing, which sequences a panel of cancer related genes, including BRAF. These 
patients include lower grade glioma (WHO Grade I and II) as well has higher grade 
gliomas (WHO Grade III and IV) of various histologies. Of 462 analyzed gliomas, 10 
point mutations were recorded, of which 4 were BRAF-V600E. 
There were 4 recorded BRAF fusions. Two tumors had in-frame 
BRAF:KIAA1549 mutations, while single reports of BRAF:CCDC6 and 
BRAF:FAM131B were recorded. Finally, 9 patients had BRAF copy number gain. 
Next, we looked at the set of Grade IV glioblastoma tumors analyzed by the TCGA 
project. Of these 273 tumors, 5 had V600E mutations, while 1 patient had a mutation 
elsewhere. 
 Overall, this suggests that BRAF is indeed recurrently mutated in gliomas. The 
most common mutation in BRAF is the canonical BRAF-V600E mutation, although 
this mutation only appears to be mutatured at a frequency at around 1% of tumors. 
BRAF fusions are very common in lower grade tumors like PA and PMA where they 
make up substantial proportions of the populations of these tumors. Indeed, BRAF 
fusions are considered diagnostically indicative of PA in the clinic. While the 
proportion of BRAF-V600E mutations appears to be slightly higher as calculated by 
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Horbinski, this is likely because literature resources are biased towards finding and 
describing these mutations. Similarly, IMPACT and TCGA are more unbiased in 
which tumors are analyzed. However, the boas of IMPACT testing towards including 
lower grade gliomas is revealed in the frequency of BRAF fusions detected. 
 
Figure 2-2. Localization of BRAF mutations in glioma. Shown are all mutations 
identified in the TCGA and IMPACT dataset. The most common mutation 
observed is a hotspot valine to glutamate mutation at codon 600.  
 
We next mapped the missense mutations reported by IMPACT testing and in 
the TCGA data set of tumors (Figure 2-2). By far the most frequent mutation was the 
canonical BRAF-V600E mutation in the kinase domain on BRAF. Interestingly, of the 
539 tumors in the IMPACT data set with BRAF mutations (out of a total 9235 
tumors), only the G446, G469A, and G596D mutations were reported in tumors of any 
other type. All other BRAF mutations were unique to glioma in the IMPACT 
database. However, some of these mutations, like S614, have been described in 
melanoma by others (Chiappetta). 
The G466, G469, and G596 mutations are also recurrent hotspots that are 
mutated both within and across tumor types, as measured by Chang (Chang et al., 
2016), though at lower frequencies much lower than V600E. These mutations have 
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been functionalized. Mutations at G469 greatly stimulate BRAF activity and are 
insensitive to vemurafenib (Yao et al., 2015b). Mutations at G466 and G596 actually 
have impaired kinase activity than wild type BRAF, but induce oncogene MEK 
signaling through increased dimerization and activation with CRAF(Kamata et al., 
2010).  
From this, we conclude that while V600E is the most common mutational 
hotspot in glioma, other mutations recurrently found in other tumor types suggest that 
BRAF activation is a common feature of all of these tumor types.  
Figure 2-3. Identification of four human glioblastoma cell lines with BRAF 
mutations. Shown are DNA sequencing results from 33 human glioma cell lines. 
Genomic DNA was isolated from 33 glioma cell lines and then sequenced on an 
Ilumina MiSeq next generation sequencing instrument to a depth of ~200-500 reads. 
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 We next sought to identify cell lines with the BRAF-V600E mutation that we 
could use to study BRAF signaling. We isolated genomic DNA from a panel of human 
glioma cell clines and used high throughput DNA sequencing. By sequencing to a 
depth of 200-500 reads, we could determine if BRAF-V600E mutations were present 
and their allelic frequencies.  
 We found four cell lines with BRAF-V600E mutations: AM38, DBTRG, 
NMCG1, and KG1C (Figure 2-3). All 4 cell lines had a BRAF c.1799 T>A 
transversion resulting in a valine 600 to glutamic acid mutation. Of the total 228 
sequencing reads for AM38, 98% were mutant, indicating that AM38 has a 
homozygous BRAF mutation. All other cell lines had about a 50% allelic frequency of 
BRAF-V600E, indicating that they possessed both a wildtype and mutant copy of 
BRAF. The allelic frequency for DBTRG was 31%, possibly suggesting aneuploidy at 
the BRAF locus. Nevertheless, there were sufficient reads of the BRAF-V600E allele 
to conclude that they had at least one copy of the BRAF-V600E allele. 
 The other 29 cell lines we sequenced were all wildtype for BRAF across their 
entire coding sequences. 
  
  
47 
 
 
 
Figure 2-4. BRAF-V600E mutant glioma cell lines have high levels of 
phosphorylated MEK and ERK protein. (A) Simplified depiction of BRAF 
pathway signaling. (B) Immunoblot of whole cell lysates from seven different human 
cancer cell lines with RAS or BRAF-V600E mutations. The name of the cell line and 
mutation is indicated above each lane.  were subjected to immunoblot analysis for the 
indicated proteins. NSCLC – Non-small cell lung cancer; CRC – colorectal cancer. 
 
 After identifying 4 cell lines with BRAF-V600E mutations, we next sought to 
determine if mutant-BRAF signals similarly in glioma and melanoma. We compared 
the four BRAF-mutant glioma cell lines to two RAS-mutant cell lines—the non-small 
cell lung cancer cell line H1299 and the colorectal cell line HCT116—as well as the 
BRAF-mutant melanoma cell line A375.  
H1299 and HCT116 both had activated MEK and ERK signaling as 
determined by immunoblot for phosphorylation of MEK at S217 and S221 (pMEK), 
and of ERK at T202 and Y204 (pERK) (Figure 2-4). However, they had much lower 
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levels of pMEK and pERK than both BRAF-mutant A375 and the BRAF-mutant 
glioma cell lines, which uniformly possessed very high levels of pMEK and pERK.  
The observation that the RAS-mutant cell lines have lower levels of pMEK 
and pERK despite having constitutively active RAS is consistent with the model that 
although RAS mutations are constitutively activating, they are sensitive to ERK-
dependent feedback inhibition of components of RAS and RAF signaling(Pratilas et 
al., 2009). Conversely, BRAF-V600E is insensitive to this feedback and therefore has 
much higher levels of pERK and pMEK. 
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Figure 2-5. Knockdown of BRAF impairs growth of BRAF-V600E mutant glioma 
cell lines. (A) Immunoblot of whole cell lysates from BRAF-V600E glioma cell lines 
which were engineered to stably express a doxycycline inducible BRAF shRNA 
cassette and were treated with vehicle (lanes 1,3,5) or doxycycline (2 μg/ml) (lanes 
2,4,6) for three days prior to lysis. (B) Graph of the relative signal intensity of pERK 
to total ERK or pMEK to total MEK for the immunoblot in (1-5A) (C) Effect of 
doxycycline induced BRAF knockdown on the growth and induction of cell death of 
BRAF-V600E glioma cell lines. Cells stably expressing a doxycycline inducible 
shRNA vector to BRAF were grown in vehicle or doxycycline (2 μg/ml) and the 
number of viable cells were counted in a trypan blue exclusion assay after the 
indicated number of days. 
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 After determining that mutant-BRAF results in high pMEK and pERK 
signaling, as it does in melanoma, we next wanted to determine if BRAF-mutant 
glioma is dependent on constitutive BRAF signaling for proliferation. To do so, we 
knocked down BRAF protein by generating BRAF-mutant glioma cells lines which 
stably express a doxycycline inducible shRNA to BRAF. Treating these cells with 
doxycycline knocked down BRAF protein in all three cell lines (Figure 2-5A).  
BRAF knockdown also resulted in concomitant decreases in pERK and pMEK 
signaling. This doxycycline induced decrease in pMEK and pERK, quantitated in 1-
5B, was greater than 50% of the vehicle treated cells in all cell lines. This indicates 
that lowering the amount of BRAF-V600E protein effectively decreases signaling flux 
through the pathway. 
ERK signaling has many biological roles, but one of its primary outputs is 
stimulation of cellular proliferation. Therefore, we next asked if BRAF knockdown 
could inhibit the proliferation of BRAF-mutant glioma cells. To do so, we plated the 
BRAF-mutant glioma cell lines into doxycycline or vehicle for three days to deplete 
them of BRAF protein, then plated them in replicates and counted the number of 
viable cells at 2 and 5 days post-plating. Doxycycline induction of BRAF knockdown 
significantly decreased proliferation in all three cell lines (Figure 2-5C). DBTRG cells 
were the most sensitive to BRAF knockdown and were almost completely growth 
arrested. While BRAF knockdown caused a significant decrease in proliferation, it did 
not affect cell viability as measured in a trypan blue exclusion assay. We observed no 
induction of cell death above background in all three cell lines (Figure 2-D). This is 
consistent with the main phenotypic output of ERK signaling affecting proliferation 
and cell growth rather than survival and apoptosis. This confirms that BRAF-mutant 
glioma cells are dependent on BRAF-V600E for both MEK and ERK signaling as well 
as for tumor maintenance, but not for cell survival. 
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Under physiological conditions, either RAS-GTP dependent 
heterodimerization (for example, BRAF/CRAF) or homodimzerization (for example, 
BRAF/BRAF) of RAF proteins is required for RAF signaling (Lavoie and Therrien, 
2015). However, in BRAF-mutant tumors, BRAF is thought to signal as a monomer 
because high levels of ERK-dependent feedback prevent the accumulation of 
sufficient levels of RAS-GTP to cause the formation RAF dimers, leaving BRAF in a 
predominantly monomeric state. To confirm the hypothesis that CRAF is dispensable 
for BRAF-mutant signaling in BRAF-mutant glioma, we knocked down CRAF 
protein by generating BRAF-mutant glioma cells lines which stably express a 
doxycycline inducible shRNA to RAF1. 
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Figure 2-6. CRAF knockdown does not reduce MEK/ERK activity or growth of 
BRAF-V600E mutant glioma cells (A) Immunoblot of whole cell lysates from 
BRAF-V600E glioma cell lines which were engineered to stably express a 
doxycycline inducible RAF1 (CRAF) shRNA cassette and were treated with vehicle 
(lanes 1,3,5) or doxycycline (2 μg/ml) (lanes 2,4,6) for three days prior to lysis. (B) 
Effect of doxycycline induced CRAF knockdown on the growth BRAF-V600E glioma 
cell lines. Cells stably expressing a doxycycline inducible shRNA vector to BRAF 
were grown in vehicle or doxycycline (2 μg/ml) and the number of viable cells were 
counted in a trypan blue exclusion assay after the indicated number of days. 
 
Doxycycline induced CRAF knockdown was effective in all three BRAF-
mutant cell lines tested (Figure 2-6A). However, in contrast to BRAF knockdown, 
CRAF knockdown resulted in no perturbation of pMEK and pERK signaling. 
Furthermore, CRAF knockdown also had no effect on the proliferation of the three 
BRAF-mutant cell lines (Figure 2-B). This is consistent with current models of BRAF 
signaling, suggesting that CRAF is not a necessary heterodimerization partner for 
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mutant-BRAF nor do CRAF/CRAF homodimers play a significant role in MEK/ERK 
signaling in mutant-BRAF tumors. 
BRAF phosphorylated and activates its only known substrates MEK1 and 
MEK2 to transduce its signal. To confirm the role of MEK-ERK signaling in mutant-
BRAF glioma we employed the highly potent and selective allosteric MEK inhibitor 
trametinib. Trametinib binds to a site adjacent to the MEK kinase domain and rapidly 
inhibits its kinase activity. 
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Figure 2-7. MEK kinase activity is required for proliferation of BRAF-V600E 
glioma. BRAF-mutant glioma cell lines were plated in various doses of trametinib for 
5 days, then counted in a trypan blue exclusion assay. Normalized cell counts were 
plotted and the resulting growth inhibition curves plotted in Prism Graphpad. 
Immunoblots of each cell line treated with trametinib are shown. 
 
 Trametinib significantly inhibits the proliferation of all three mutant-BRAF 
glioma cell lines, with IC50s ranging between 0.5 and 1.5 nM trametinib, similar to 
the IC50 of the BRAF-mutant cell line A375 (Figure 2-7). This inhibition of 
proliferation indicates that MEK kinase activity is necessary to BRAF-mutant tumors, 
confirming the role of MEK in transducing activated BRAF signaling. This activity is 
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further consistent with trametinib being FDA approved for the treatment of BRAF-
mutant metastatic melanoma where it has achieved quite some success.  
 
Discussion 
 
While BRAF mutations are not as common in glioma as they are in other 
tumor types like melanoma, it is important to understand their biology. BRAF-V600E 
mutations directly drive MEK/ERK signaling in glioma. We demonstrated this by 
showing that they have high levels of pMEK and pERK and  further demonstrated that 
knockdown of BRAF protein lowers signaling through MEK and ERK by using a 
shRNA to BRAF. Finally, we showed that MEK kinase activity is required for the 
proliferation of BRAF-mutant melanoma. Inhibited MEK kinase activity with an 
inhibitor potently slows the proliferation of BRAF-mutant glioma like it does in 
BRAF-mutant melanoma. 
While much work has been devoted specifically to understanding BRAF-
V600E mutations in many tumor types, it is interesting to think of the other BRAF 
mutations that occur in gliomas. The fact that other highly activating BRAF mutations, 
like the G469 mutation, and the CRAF activating G466 and G596 mutations occur 
suggests that activated BRAF signaling is likely important to certain gliomas outside 
of the V600E context specifically. 
Furthermore, some BRAF mutations are found at at higher frequencies than 
BRAF-V600E to the point that they are even considered diagnostic in some cases. 
This further suggests that when mutationally activated, BRAF likely plays a 
significant role in many types of gliomas. Its possible that being able to understand its 
biology in the V600E context will help us to understand it in other contexts. 
  
56 
 
CHAPTER 3: EFFECTS OF VEMURAFENIB IN BRAF-MUTANT GLIOMA. 
 
Introduction 
 
 After the discovery of the V600E mutation in melanoma, several groups set out 
to validate it as a therapeutic target. Following studies that BRAF-V600E mutant cell 
lines were highly sensitive to genetic ablation of BRAF and the creation of genetic 
engineered mouse models of mutant-BRAF driven cancers, the pharmaceutical 
industry set out to identify selective inhibitors of BRAF. 
 The first of these drugs to be FDA approved was the drug vemurafenib, 
approved in 2011 for BRAF-V600E mutant metastatic melanoma. In vitro, 
vemurafenib showed a slight selectivity for mutant-BRAF over wild-type BRAF. In 
vivo, the drug potently inhibited utant-BRAF signaling, extinguishing pMEK and 
pERK signaling, and leading to dramtic reductions in tumor volume. However, the 
drug only inhibited mutant-BRAF signaling. In fact, the drug hyperactivated wild-type 
BRAF signaling in cells with activated RAS, a phenomenon known as the RAF-
inhibitor paradox. 
 BRAF inhibitors have been tested in various tumor types. In fact, a current 
type of clinical trial known as a “basket trial” enrolls a patient with any tumor type 
provided that he or she has a given mutation. While responses to vemurafenib and 
similar drugs has been quite dramatic in melanoma, the response in other tumor types 
has been more heterogeneous. Therefore, we first sought to describe the acute and 
long term biochemical and biological response of BRAF-mutant glioma to 
vemurafenib in order to help us understand whether or not this drug might be 
effective. 
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Results 
 
We first treated BRAF-mutant glioma cells with a range of doses of 
vemurafenib encompassing the typical IC50 of a BRAF-mutant cell line (Figure 3-
1A). At higher doses (10 μM) of vemurafenib, pMEK and pERK are completely 
inhibited. As the concentration of vemurafenib decreases, pMEK and pERK increase. 
From the immunoblot, we estimate that the IC50 of pMEK and pERK inhibition is 
between 100 and 1000 nM vemurafenib. We plotted the inhibition curves of pERK in 
response to vemurafenib and confirmed that the IC50s fall between 100 and 200 nM 
vemurafenib. 
Figure 3-1. Biochemical effects of short-term (1 hour) treatment of BRAF-V600E 
GBM cells with vemurafenib. (A) Immunoblot of whole cell lysates from BRAF-
mutant glioma cell lines treated with vemurafenib for 1 hour. (B) Relative signal 
intensity of phosphorylated ERK to total ERK from (2-1A) was calculated and the 
resulting inhibition curve plotted in GraphPad Prism. 
 
 Interestingly, AM38 appears to have some residual pMEK and pERK even at 
the highest doses of vemurafenib (Figure 3-1A). Three cell lines express relatively 
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similar levels of total BRAF protein (see Figure 3-5A). However, the BRAF antibody 
does not distinguish between wildtype and mutant BRAF protein. AM38 has a 
homozygous BRAF-V600E mutation (see Figure 3-3), so while the BRAF signal for 
DBTRG and NMCG1 is split between mutant and wildtype-BRAF, the entire BRAF 
signal for AM38 must be all mutant-BRAF. High levels of mutant-BRAF protein can 
induce the formation of BRAF-V600E homodimers (Shi et al., 2012). Vemurafenib 
only inhibits monomeric mutant-BRAF, so we hypothesize that the residual signal in 
AM38 is due to the formation of some BRAF-mutant homodimers that become 
transactivated in the presence of vemurafenib. 
 After confirming that vemurafenib can effectively inhibit BRAF-V600E in 
BRAF-mutant glioma, we next sought to compare the acute IC50 for pERK inhibition 
with that of a panel of BRAF-mutant melanoma lines to determine if mutant BRAF 
protein could be similarly inhibited in both tumor types. Using a more granular 
dilution series of vemurafenib, we treated a panel of BRAF-mutant glioma and 
melanoma cell lines for one hour and then visualized the amount of pERK and total 
ERK protein using an immuno-infrared assay (Figure 3-2A). The IC50 for pERK 
visually appears to be very similar in all three cell lines of each type. 
 We then calculated the signal intensity of pERK and total ERK in each well 
and plotted the resulting inhibition curves to determine the IC50 for vemurafenib 
induced pERK inhibition. The IC50s for all the cells lines were almost identical, 
falling between the range of 80-180 nM vemurafenib for BRAF-mutant glioma and 80 
and 110 nM for BRAF-mutant melanoma. AM38 again had a slightly higher IC50 and 
the greatest amount of residual pERK. We again hypothesize that this is due to the 
formation of a small amount of vemurafenib-insensitive mutant-BRAF homodimers 
for the above mentioned reasons. 
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 From this data we conclude that there are no significant differences between 
the biochemical identities of the BRAF-V600E protein in BRAF-mutant glioma and in 
BRAF-mutant melanoma, as it can be inhibited by vemurafenib at very similar 
concentrations. 
 
 
Figure 3-2. Comparison of short term (1 hour) vemurafenib IC50s between 
BRAF-V600E glioblastoma and melanoma cell lines. Shown are data from an 
immuno-infrared assay. (A) BRAF-mutant glioma and melanoma cells were treated 
with 3-fold dilutions of vemurafenib for 1 hour, fixed and permeabilized, then stained 
with IR-dye conjugated antibodies to total ERK (red) and phosphorylated-ERK 
(green). Representative images are shown. (B) Relative signal intensity of 
phosphorylated ERK to total ERK from (2-2A) in each well was calculated and the 
resulting inhibition curve plotted and IC50 calculated in GraphPad Prism. Error bars 
have been omitted for clarity. 
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 After confirming that vemurafenib is able to inhibit mutant-BRAF signaling in 
BRAF-mutant glioma after one hour of treatment, we next asked whether vemurafenib 
continued to inhibit mutant-BRAF signaling over a longer period of treatment. We 
used 2 μM vemurafenib, a dose that inhibits most pMEK and pERK after one hour of 
treatment (Figure 3-3A). After confirming near complete inhibition of pMEK and 
pERK after one hour of treatment with vemurafenib, we then compared it to the level 
of pERK inhibition after 48 hours of treatment. We observed that pERK levels 
rebounded after 48 hours of vemurafenib treatment. Quantifying the pERK to total 
ERK signal revealed that this rebound was between 25-70% of the original pERK 
signal (Figure 3-3B).  
Figure 3-3. Rebound activation of ERK after 48 hours of vemurafenib treatment 
in BRAF-mutant glioma. (A) Immunoblot of whole cell lysates from BRAF-mutant 
glioma cells treated with vemurafenib for the indicated times. (B) Graph of the relative 
signal intensity of phosphorylated ERK to total ERK from (2-3A). 
 
61 
 
 Rebound of pERK in the presence of vemurafenib is a well-documented 
phenomenon and most often is associated with the relief of negative feedback 
activating CRAF, leading to the formation of vemurafenib-insensitive BRAF/CRAF 
dimers (Samatar and Poulikakos, 2014). A high magnitude of this negative feedback 
relief is often associated with a lack of biological response to vemurafenib. However, 
it has also been shown that BRAF-mutant melanoma cells, which in general are 
sensitive to vemurafenib can also have some amount of pERK rebound through the 
same mechanisms. 
 Therefore, we sought to compare the magnitude of pERK rebound in BRAF-
mutant glioma versus BRAF-mutant melanoma. Using the same concentration of 
vemurafenib, we studied the kinetics of pERK rebound in a panel of BRAF-mutant 
glioma and BRAF-mutant melanoma cell lines in a time course of vemurafenib 
treatment, collecting samples at several time points across 48 hours of treatment. 
Figure 3-4. Kinetics of ERK reactivation following vemurafenib treatment in 
BRAF V600E GBM cells. pERK begins to rebound within 24 hours in BRAF-mutant 
glioma cells, but not in BRAF-mutant melanoma cells. (A) Immunoblots of whole cell 
lysates from BRAF-mutant human cancer cell lines treated with vemurafenib for the 
indicated times. (B) Graph of the ratio of signal intensity of phosphorylated ERK to 
total ERK relative to DMSO from (2-4A). 
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 As seen before, pERK rebounds in BRAF-mutant glioma within 48 hours 
(Figure 3-4A). In DBTRG, pERK rebound becomes pronounced at 24 hours. In 
AM38 and NMCG1, pERK rebound begins even sooner, within 8 hours of 
vemurafenib treatment. Conversely, pERK remains inhibited in a panel of BRAF-
mutant melanoma cell lines for up to 48 hours with only a very slight amount of pERK 
rebound observed. By quantitating the ratio of pERK to total ERK at each time point 
relative to the initial ratio pf ERK activation, it becomes evident that there is a greater 
amount of pERK rebound in all three mutant-BRAF glioma lines relative to the three 
melanoma cell lines (Figure 3-4B). This demonstrates that while pERK remains 
durable inhibited in BRAF-mutant melanoma, pERK does not remain inhibited by 
vemurafenib in BRAF-mutant glioma, rebounding throughout long term treatment. 
 Although ERK phosphorylation is required for its activity, it is not a very exact 
measure of total ERK activity because ERK also regulates its own phosphorylation 
through upregulating dual specificity phosphatases (DUSPs). Therefore, we wanted to 
see if rebound in pERK was associated with a rebound in ERK activity. 
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Figure 3-5. Incomplete inhibition of the ERK target gene Cyclin D1 by 
vemurafenib in BRAF-V600E mutant GBM cells. BRAF-V600E mutant cancer 
cells were treated with vemurafenib for the indicated times, then whole cell lysates 
were subjected to immunoblot analysis for the indicated proteins. 
 
 We measured the protein expression of the protein Cyclin D1, whose 
transcription is directly upregulated by activated ERK during a time course of 
vemurafenib treatment. Cyclin D1 levels remain constant, or initially fall only slightly, 
after a few hours of vemurafenib treatment in BRAF-mutant glioma (Figure 3-5). 
However, by 24-48 hours, Cyclin D1 expression also rebounds. Conversely, Cyclin 
D1 expression levels fall towards the threshold of detection in the BRAF-mutant 
melanoma cell lines. Total levels of remaining Cyclin D1 expression remain much 
higher in vemurafenib treat BRAF-mutant glioma than BRAF-mutant melanoma. 
 Cyclin D1 is a cell cycle protein whose expression is necessary for the 
transition between G1 and S-phase. Growth factor stimulation of ERK activation 
upregulates expression of this Cyclin D1, ushering the cell forward through the cell 
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cycle. Blocking expression of Cyclin D1 can growth arrest cells. Because of this, we 
asked if incomplete Cyclin D1 repression in vemurafenib treated BRAF-mutant 
glioma cells was also associated with incomplete growth repression by vemurafenib. 
 
 
 
Figure 3-6. BRAF-V600E GBM cells are less sensitive to growth inhibition by 
vemurafenib than BRAF-V600E melanoma cells. (A) Cells were plated into various 
concentrations of vemurafenib and grown for 5 days, then counted in a trypan blue 
exclusion assay. Normalized cell counts were plotted and the resulting growth 
inhibition curves plotted in Prism Graphpad. Boxed data is reproduced in (B), a graph 
of the number of cells as a percent of the vehicle treated cells for each cell line treated 
with 1 μM vemurafenib. 
 
We measured the proliferation of a panel of BRAF-mutant glioma and 
melanoma cell lines in the presence of various doses of vemurafenib for 5 days of 
growth (Figure 3-6A). While the total proliferation of all cell lines was reduced by 
some amount of vemurafenib treatment, the IC50s for the BRAF-mutant glioma lines 
were all right shifted relative to those for BRAF-mutant, demonstrating that these lines 
are intrinsically less sensitive to vemurafenib.  
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The residual rate of growth in the presence of 1 μM vemurafenib was also 
much higher in the BRAF-mutant glioma cell lines than in the BRAF-mutant 
melanoma cell lines (Figure 3-6B). The BRAF-mutant melanoma cell lines had, on 
average, less than 20% growth of the vehicle treated cells, while the BRAF-mutant 
glioma cell lines had on average about 40% of the growth of the vehicle treated cells, 
demonstrating that they had less total growth suppression than the BRAF-mutant 
melanoma cell lines. 
Finally, we wanted to compare the sensitivity of BRAF-mutant glioma cells to 
another BRAF-mutant context which is known to become insensitive to vemurafenib 
through relief of negative feedback. When treated with vemurafenib, ERK-dependent 
inhibition of HER3 and its ligand NRG1 are relieved, and pERK rebounds. 
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Figure 3-7. BRAF V600E GBM resemble BRAF V600E thyroid cancer cells in 
the kinetics of ERK rebound activation and incomplete growth inhibition. (A) 
BRAF-mutant thyroid cells were treated with vemurafenib for the indicated times, 
then whole cell lysates were subjected to immunoblot analysis for the indicated 
proteins. (B) Cells were plated into various concentrations of vemurafenib and grown 
for 5 days, then counted in a trypan blue exclusion assay. Normalized cell counts were 
plotted and the resulting growth inhibition curves plotted in Prism Graphpad. Boxed 
data is reproduced in (C), a graph of the number of cells as a percent of the vehicle 
treated cells for each cell line treated with 1 μM vemurafenib. 
 
 We treated two thyroid cell lines with 2 μM vemurafenib for the same amounts 
of time as in Figure 3-4 and 2-5 and measured the amount of pERK rebound and 
correlated that with Cyclin D1 repression. As expected, pERK rebounded from being 
inhibited quickly, though vemurafenib failed to achieve the same amount of inhibition 
at 1 hour in the BRAF-mutant thyroid lines compared to BRAF-mutant glioma and 
BRAf-mutant melanoma (Figure 3-7A). Furthermore, the amount of pERK rebound 
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was much more pronounced in the thyroid cell lines, suggesting the relief of negative 
feedback in BRAF-mutant thyoid cell lines leads to pronounced reactivation of the 
pathway. 
 We also measured the growth inhibition of vemurafenib in the BRAF-mutant 
thyroid cell lines and compared it to the BRAF-mutant glioma and BRAF-mutant 
melanoma cell lines (Figure 3-7B). The IC50 for BRAF-mutant thyroid were further 
right shifted from those of BRAF-mutant melanoma, indicating that they two were 
much less sensitive to vemurafenib. This is further represented by the amount of 
growth suppression in the presence of 1 μM vemurafenib (Figure 3-7C). The thyroid 
cell lines still had on average about 50% of the growth of the vehicle treated samples. 
 From this we conclude that BRAF-mutant glioma is similar to BRAF-mutant 
thyroid cells in that both have pronounced reactivation of ERK signaling following 
vemurafenib treatment and are relatively insensitive to vemurafenib compared to 
BRAF-mutant melanoma. 
 
Discussion 
 
Interrogating BRAF-mutant glioma with vemurafenib on a short time scale 
suggests that these tumors might be very similar. Their biochemical IC50s for acute 
ERK inhibition are nearly identical. However, when looking on a longer time scale, it 
become more evident that BRAF-mutant glioma is actually quite different from 
BRAF-mutant melanoma. While vemurafenib quite potently inhibits pERK for 48 
hours post treatment in BRAF-mutant melanoma, pERK rebounds within 24 hours, or 
even sooner, in BRAF-mutant glioma treated with vemurafenib. This pERK rebound 
is associated with incomplete Cyclin D1 repression and decreased sensitivity to 
vemurafenib. 
68 
 
These observations further underscore the importance of biochemical pERK 
rebound and connecting it with a phenotypic outcome. Cell lines with a pronounced 
rebound in pERK fail to durably inhibit Cyclin D1 transcription and expression. They 
are also less growth arrested by vemurafenib. Presumably, a lack of Cyclin D1 
expression plays a role in the lack of growth arrest by vemurafenib in BRAF-mutant 
glioma. 
Rebound in pERK has very important clinical ramifications. The extent of 
pERK inhibition in vemurafenib treated patients is highly correlated with clinical 
response. Preclinical models have demonstrated that BRAF inhibitors require 
complete ERK inhibition in order to result in tumor regressions (Bollag et al., 2010). 
Patients whose tumors bear residual pERK relapse sooner than those who do not. 
This also explains why tumors may try to upregulate pERK in order to escape 
the anti-oncogenic effects of BRAF inhibition. The fact that pERK is initially inhibited 
in BRAF-mutant glioma before rebounding suggests that these cells escape 
vemurafenib though an adaptive response, rather than an acquired mutation or de novo 
resistance mechanism. 
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CHAPTER 4: VEMURAFENIB RELIEVES ERK-DEPENDENT 
FEEDBACK ON RAS-ERK SIGNALING 
 
Introduction 
 
Not all BRAF-mutant tumors have dramatic responses to BRAF inhibitors like 
vemurafenib. For instance, in Phase I trials of vemurafenib in BRAF-mutant colorectal 
(CRC) and thyroid tumors, very few objective tumor responses were recorded (Kopetz 
et al., 2010). The general unresponsiveness of these tumors turned out to be the result 
of adaptive responses to mutant-BRAF inhibition. The first of these adaptive 
responses to be thoroughly described was transient ERK inhibition with vemurafenib 
in CRC. Phospho-ERK rebounded through EGFR-mediated reactivation of the 
pathway by inducing the formation of vemurafenib insensitive BRAF/CRAF dimers 
(Corcoran et al., 2012; Prahallad et al., 2012). Blocking both EGFR and BRAF lead to 
tumor regressions. 
Similarly, in BRAF-mutant thyroid tumors, vemurafenib treatment also results 
in transient pERK inhibition (as we replicated in Figure 3-7). This turned out to be an 
adaptive response through relief of ERK-dependent negative inhibition of HER3 
receptor as well as its ligand NRG1 (Montero-Conde et al., 2013). Blocking HER 
kinase activity with lapatinib in combination with a BRAF inhibitor was sufficient to 
block pERK rebound and induce tumor regressions in preclinical models. 
Using these findings as a model for candidates of BRAF-inhibitor adapative 
responses, we sought to determine if any ERBB family members were subject to 
ERK-dependent feedback activation and might mediate pathway reactivation 
following BRAF inhibition. 
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Results 
 
 Because most of the adaptive responses to BRAF-inhibition occurred through 
ERBB family members, we considered them our first candidates for mediating the 
vemurafenib insensitivity of BRAF-mutant glioma. 
 The ERBB family is composed of 4 receptors, EGFR, HER2, HER3, and 
HER4 (summarized in Figure 4-1) (Hynes and Lane, 2005). Upon stimulation with an 
ERBB-ligand, the receptors dimerize and signal through downstream effector 
pathways. HER2 receptor has no known ligands, so it primarily serves as the preferred 
co-receptor for all other ERBB family members. HER3 has no intrinsic kinase 
activity, so it must form heterodimers as well in order to signal. 
 There are ten ERBB ligands. The first family of ligands—epidermal growth 
factor (EGF), amphiregulin (AREG) and transforming growth factor‐α (TGFα)—bind 
specifically to EGFR. The second family, composed of betacellulin (BTC), heparin‐
binding EGF (HB‐EGF) and epiregulin (EREG) can bind both EGFR and HER4. 
Neuregulins (NRG) 1, 2, 3, and 4 comprise the last two families. NRG1 and NRG2 
can bind both HER3 and HER4 while NRG3 and NRG4 are specific to only to HER4. 
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Figure 4-1. The ERBB family of ligands and their receptor specificities. There are 
4 family members in the ERBB receptor tyrosine kinase family—EGFR, HER2, 
HER3, and HER4—as well as 10 ligands with various specificities for those receptors 
as well as the ability to induce specific dimerization partners. (Adapted from 
Olayioye, M. et al, EMBO 2000). 
 
We first asked if any of the ERBB family member receptors, or their ligands, 
were transcriptionally activated in response to vemurafenib treatment in BRAF-mutant 
DBTRG cells. We treated DBTRG cells with vemurafenib for various time points then 
collected and isolated RNA and quantitated ERBB family member and ligand 
transcript levels through QPCR.  
We first verified that the drug treatment worked by looking at two genes which 
are directly upregulated by ERK activity (Figure 4-2A). The product of these genes, 
DUSP6 and SPRY4, negatively regulate ERK activity. DUSP6 dephosphorylates and 
inactivates ERK while SPRY4 disconnects RTK signaling from RAS. Both of these 
genes serve to limit ERK activation under physiological conditions. However, when 
mutant-BRAF is inhibited, loss of expression of these genes can serve to augment 
pERK reactivation.  
DUSP6 expression rapidly fell to 25% of its original level after vemurafenib 
treatment, before falling further to 10% of its original level at 24 hours. The kinetics of 
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SPRY4 repression were slower, but by 24 hours, SPRY4 had fallen to 25% of its 
original level. Both of these genes then slowly rebounded over the following 5 days, 
indicative of the rebound in pERK and its activity seen in the last chapter. 
 
Figure 4-2. Vemurafenib induces transcription of selected ErbB family ligands 
and receptors in BRAF V600E GBM cells (DBTRG cell line). (A), (B), and (C). 
Relative expression of the indicated genes was quantified by QPCR from RNA 
isolated from DBTRG BRAF-mutant glioma cells treated with 2 μM vemurafenib for 
the amounts of time specified. EGF – epidermal growth factor; AREG - amphiregulin; 
TGFA - transforming growth factor-α; BTC – betacellulin; HBEGF - heparin-binding 
EGF; EREG – epiregulin; NRG – neuregulin. 
 
 We then looked at the expression of the ERBB receptors EGFR, ERBB2, 
ERBB3 and ERBB4 (Figure 4-2B). Only ERBB2 was significantly upregulated, rising 
by 3 fold over the five days of vemurafenib treatment. ERBB4 and EGFR remained 
relatively constant, while ERBB3 interestingly fell by 50%. From the total receptor 
analysis, we hypothesize that HER3 may have a role in facilitating the adaptive 
response leading to vemurafenib insensitivity. 
 Finally, we looked at the transcription of the EGF family of ligands (Figure 4-
2C). All of the ligands remained unchanged during the five days of vemurafenib 
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treatment except for BTC, which was upregulated by 10-15 fold, and NRG4, which 
was upregulated 20-fold by the end of the experiment. NRG4, recall, is a specific 
ligand for only HER4, while BTC activated both EGFR and HER4. From this 
analysis, we hypothesize that EGFR and HER4 may play a role in facilitating the 
adaptive response leading to vemurafenib insensitivity.  
 We next sought to verify if the changes in transcript levels were reflected in 
changes at the protein level. We collected whole cell lysates from DBTRG cells 
treated with vemurafenib for various amount of time (Figure 4-3A). Total HER2 
levels were upregulated 4-fold above DMSO. We also looked at the primary tyrosine 
autophosphorylation sites of EGFR, HER2, and HER3 which typically indicate that 
they are being activated (Figure 4-3B). All three phosphorylation sites rose relative to 
DMSO in response to vemurafenib treatment, with them most dramatic changes in 
EGFR and HER2. 
 The results in Figure 4-3 are largely consistent with those from Figure 4-2. 
Total ERBB2 transcript levels rose, and this was reflected in a rise in total HER2 
protein levels. The ligands upregulated suggest that EGFR and HER4 should be the 
most highly activated of the ERBB family members. Indeed, EGFR-Y1068 (pEGFR) 
did modestly rise. However, all of the ERBB family member receptors can 
heterodimerize, so the more dramatic changes in HER2-Y1248 (pHER2) and HER3-
Y1289 (pHER3) could possibly be HER4 heterodimers. 
 
74 
 
 
Figure 4-3. Immunoblotting confirms vemurafenib induced upregulation of 
selected ErbB pathway members in BRAF V600E mutant GBM cells (DBTRG 
cell line) Long term vemurafenib treatment increases HER2 receptor levels and 
EGFR, HER2, and HER3 activation. (A) DBTRG cells were treated with 2 μM 
vemurafenib for the indicated times, then whole cell lysates were subjected to 
immunoblot analysis for the indicated proteins. (B) Graph of the ratio of signal 
intensity of indicated proteins to total ERK relative to their initial DMSO treated 
expression from (3-3A). 
 
 After observing rises in ERBB receptor and ligand transcript levels, and well 
as increases in the receptor protein levels and their activation, we then wanted to know 
if EGFR and/or HER2 kinase acticity were responsible for mediating pERK rebound 
and vemurafenib resistance. To do this, we employed the highly selective EGFR and 
HER2 kinase inhibitor lapatinib. We treated DBTRG cells with vemurafenib alone or 
in combination with lapatinib to see if adding an ERBB kinase inhibitor would blunt 
the rebound in pERK. 
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Figure 4-4. Inhibition of EGFR and HER2 kinase activity is not sufficient to 
blunt vemurafenib-induced feedback activation of ERK in BRAF V600E mutant 
GBM cells (DBTRG cell line). (A) Whole cell lysates from DBTRG cells treated 
with 2 μM vemurafenib alone or in combination with 2 μM lapatinib for the indicated 
amounts of time were subjected to immunoblot analysis for the indicated proteins. (B) 
Graph of the ratio of signal intensity of phosphorylated ERK to total ERK relative to 
DMSO from (4-4A). 
 
 We observed complete absence of pEGFR and pHER2, indicating that 
lapatinib completely blocked their activity. Nevertheless, we observed a very similar 
rebound in pERK in both the vemurafenib treated cells as well as those treated with 
both vemurafenib and lapatinib. This indicated that EGFR and HER2 kinase activity is 
not required to facilitate a rebound in pERK. Cyclin D1 follows the pERK activity, 
being initially inihibited and then being incompletely inhibited at 3 days. 
  This lack of biochemical activity was also reflected in a growth assay in which 
we grew DBTRG cells in vemurafenib alone or in combination with 2 μM lapatinib. 
Laptininb along inhibited the growth of DBTRG cells approximately 20%, but failed 
to provide additional growth inhibition when added to a dose rage of vemurafenib.  
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Figure 4-5. Lapatinib does not increase the sensitivity of DBTRG cells to 
vemurafenib. DBTRG cells were plated various doses of vemurafenib alone or in 
combination with 2 μM lapatinib for 5 days then counted in a trypan blue exclusion 
assay. Normalized cell counts were plotted and the resulting growth inhibition curves 
plotted in Prism Graphpad. 
 
Because the growth inhibition curves of vemurafenib with and without 
lapatinib are almost superimposable and because lapatinib failed to block 
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vemurafenib-induced pERK rebound, we conclude that EGFR and HER2 kinase 
activity alone are not responsible for the insensitivity of DBTRG to vemurafenib. 
 
 
Figure 4-6. The MET kinase inhibitor JNJ38877605 also does not sensitize BRAF 
V600E  mutant GBM cells (DBTRG cell line) to vemurafenib, (A) DBTRG were 
treated with various doses of vemurafenib for 1 hour or with 1 μM the MET inhibitor 
JNJ38877605, then whole cell lysates were subjected to immunoblot analysis for the 
indicated proteins. (B) DBTRG cells were plated various doses of vemurafenib alone 
or in combination with 1 μM JNJ38877606 for 5 days, then counted in a trypan blue 
exclusion assay. Normalized cell counts were plotted and the resulting growth 
inhibition curves plotted in Prism Graphpad. 
 
 We also noticed that DBTRG express MET receptor (Figure 4-6). MET 
receptor has also been implicated in feedback reactivation of both MAPK and PI3K 
pathways following vemurafenib treatment in BRAF mutant thyroid (Byeon et al., 
2015). We used the selective MET kinase inhibitor JNJ38877605 to inhibit MET 
78 
 
kinase activity to see if it could sensitive BRAF mutant DBTRG cells to vemurafenib 
treatment. 
 Despite effectively inhibiting MET-Y1234-5 (pMET), JNJ38877605 failed to 
further sensitize DBTRG cells to vemurafenib in a growth assay in which cells were 
treated with vemurafenib alone or in combination with the JNJ38877605. The 
vemurafenib IC50s were almost identical as were the growth inhibition curves, 
suggesting the MET kinase activity does not activate ERK signaling in DBTRG cells, 
and therefore does not mediate resistance from feedback reactivation of the pathway. 
 After eliminating the most likely candidates for feedback reactivation of ERK 
signaling, we wanted to take a more unbiased approach to identifying possible 
upregulated RTKs that could mediate reactivation of the ERK pathway through relief 
of negative feedback. To do so, we employed an RTK array which measures over 50 
phospho-proteins simultaneously. We compared all three cell lines after being treated 
with vemurafenib for 72 hours.   
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Figure 4-7. Phospho-RTK arrays fail to identify receptor tyrosine kinases that 
are induced by vemurafenib and might explain ERK rebound reactivation. (A) 
BRAF-mutant glioma cells were treated with 2 μM vemurafenib for 72 hours, lysed in 
Cell Signaling Cell Lysis Buffer, and whole cell lysates were incubated with pre-
coated RTK array slides. Membranes were stained with infrared dye conjugated 
secondary antibody and imaged on a Licor Odyssey instrument. (B) Signal intensity 
from slides was quantitated, averaged across duplicate spots, and rank ordered by 
average fold change across all three cell lines. The most significantly upregulated and 
downregulated phosphoproteins are listed. (C) Whole cell lysates collected in (3-7A) 
were subjected to immunoblot analysis for the indicated proteins. 
 
Unfortunately, we did not observe any significantly upregulated RTKs on the 
array. We noted that pERK decreased by 2-fold on average, indicating that 
vemurafenib inhibited ERK signaling. The most significantly upregulated proteins 
were Akt-T308 and Akt-S473, although these proteins increased by less than 2-fold. 
We also recorded the most significantly downregulated proteins. Interestingly, 
vemurafenib treatment resulted in dramatic decreases in pMET.  Very few proteins 
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included on this RTK array were upregulated by vemurafenib treatment. Among those 
that were are pAkt-T308 and S473. pMET was dramatically inhibited by vemurafenib 
treatment in DBTRG and to a lesser extent in AM38, further supporting the finding 
that MET inhibition would not sensitize DBTRG to vemurafenib.  
Interestingly, the RTK array also failed to pick up the more dramatic changes 
we observed by western blot in pHER2 and pHER3. We suspect that this is because 
RTKs are inherently less sensitive than immunoblots because they detect any tyrosine 
phosphorylation instead of using antibodies to the specific phosphorylation events that 
we surveyed. 
 
Discussion 
 
Is it slightly disappointing that despite observing rather dramatic changes in 
ERBB receptor and ligand transcript levels that we were still unable to pinpoint the 
RTK or RTKs primarily responsible for mediating relief of ERK-dependent feedback 
pathway reactivation. However, there are a few possible explanations for why this 
might be.  
We might hypothesize that feedback on other ERBB family memebrs besides 
EGFR and HER2 is relieved in order to reactivate pERK signaling. Our experiments 
do not rule out HER3 or HER4 as heterodimeric partners in reactivating ERK 
signaling as lapatinib only inhibits EGFR and HER2. This observation is also 
supposed by the strong activation of pHER3 we observed. We could perform co-IP 
experiments to determine which ERBB family members are the predominant dimers 
following relief of ERK-dependent negative feedback. Then, we might be able to 
useing other inhibitors, such as the antibody pertuzumab, which block the ability of 
HER2 to dimerize with other receptors. 
81 
 
However, it is also possible that there are no significant RTKs that become 
upregulated following vemurafenib treatment. Lito has demonstrated that ligand-
dependent signaling from RTKS is negatively inhibited in BRAF-mutant cells (Lito et 
al., 2012). Vemurafenib mediated relief of ERK-dependent feedback occurs on most 
of these RTKs, and instead of specifically hyper-activating one of them, allows the 
cell to become permissive to ligand mediated RTK signaling, having lost most of its 
negative feedback. In melanoma, which have relatively little basal RTK signaling, the 
rise in ERK from this increase in RTK signaling permissiveness is small, but 
detectable. Therefore, one might hypothesize that if BRAF-mutant glioma has more 
basal RTK activity than melanoma, relief of negative feedback on this RTK activity 
might be sufficient to lead to vemurafenib insensitivity.  
Using this dynamic view of feedback, it is also interesting to speculate on the 
kinetics of BTC transcript level changes (Figure 4-2). BTC initially rose 15-fold at 1 
day of vemurafenib treatment, before falling to 10-fold upregulated at 3 and 5 days of 
vemurafenib treatment. This is consistent with BTC restoring some signaling capacity 
to the ERK pathway which would in turn re-restore some of the ERK-dependent 
feedback on BTC, lowering its transcript levels somewhat, and reaching a new steady 
state.  
This dynamic process might also explain why pEGFR, pHER2, and pHER3 all 
initially rise following vemurafenib treatment in DBTRG before falling to somewhat 
lower levels (Figure 4-3). This rise in ERBB activity restore some ERK pathway 
activity which then restores some ERK-dependent feedback, lowering the amount of 
ERBB activity. 
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CHAPTER 5: RELIEF OF NEGATIVE FEEDBACK INDUCES RAS-GTP 
DEPENDENT RAF DIMERS THAT ARE RESISTANT TO VEMURAFENIB 
BUT SENSITIVE TO RAF DIMER INHIBITORS 
 
Introduction 
 
 While there are several different mechanisms for a tumor to achieve a resistant 
state, they actually all share a very common etiology based in basic RAF science. 
Under physiological conditions, RAF molecules must dimerize in order to become 
signaling competent. This dimerization is induced by the formation of RAS-GTP. 
Without sufficient levels of RAS-GTP, RAF molecules will remain in a monomeric, 
signaling incompetent state. Indeed, following pathway stimulation, ERK will exert 
negative feedback on RTKs and RAS-GTP, serving to limit pathway activation and to 
return to baseline conditions. 
 BRAF-V600E, however, has gained the ability to signal as a monomer through 
an activating mutation in its kinase domain. In fact, the high ERK out of mutant-
BRAF places very strong negative feedback on RTK/RAS components, and maintains 
the cell in a RAS-GDP state (Figure 5-1) (Lito et al., 2012, 2013). However, 
following vemurafenib treatment, this ERK-dependent negative feedback is relieved, 
and RTKs begin to stimulate activation of RAS-GTP. In the presence of RAS-GTP, 
mutant-BRAF protein forms dimers. While vemurafenib can still bind the mutant-
BRAF protomer of the induced dimers, it will transactivate the other RAF partner, 
reactivating RAF/ERK signaling, and rendering the RAF dimer insensitive to 
vemurafenib. 
 Finally, the restoration of some ERK activity will restore some of its negative 
feedback as well, lowering signaling from its rebound. This process will oscillate until 
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the cell reaches a new steady state where ERK signaling remains insensitive to 
vemurafenib. 
Figure 5-1. Tumor adaptation to BRAF inhibitors. (A) In V600E BRAF tumors, 
ERK signaling is high, as is ERK feedback inhibition of CRAF, SOS, and RTKs. 
RAS-GTP levels are therefore low, and BRAF signals as a monomer. (B) Following 
BRAF-V600E inhibitor treatment, ERK signaling and negative feedback rapidly fall. 
(C) In the absence of negative feedback, RTKs are then able to activate RAS, leading 
to a rise in RAS-GTP levels and the induction of vemurafenib-insensitive RAF dimers. 
(D) As ERK activity rebounds, so does some of its negative feedback. The cells reach 
a new steady state of ERK signaling which in insensitive to vemurafenib and sensitive 
to the amount of RTK signaling. Figure from Lito P. et al, Nature Medicine 2013.  
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 We sought to determine if the rise in RAS-GTP was responsible for mediating 
the vemurafenib insensitivity of mutant-BRAF glioma. To do so, we used a RAS-GTP 
pulldown assay. RAS-GTP pulldowns use the observation that the RAS-Binding 
Domain (RBD) of CRAF protein binds only RAS-GTP. The RAF-RBD is fused to a 
GST tag, and the RAS-GTP immunoprecipitated from whole cell lysates.  
We compared the basal levels of RAS-GTP in a panel of BRAF-mutant glioma 
cell lines. We compared these to H1299, an NRAS-mutant cell line, and HCT116, 
KRAS-mutant cell line as positive controls for RAS-GTP loading since Ras-mutant 
cell lines have lost the ability to hydrolyze GTP and therefore remain constitutively 
GTP bound. 
 As expected H1299 and HCT116 possess high levels of RAS-GTP. We then 
observed that Ras-GTP levels are almost completely feedback inhibited in BRAF-
mutant glioma cell lines, consistent with their elevated ERK output (see Figure 5-4). 
We also measured the amount of activated CRAF by probing for CRAF-S338. The 
RAS-mutant cell lines have high levels of activated CRAF, consistent with having 
high levels of CRAF-dimer signaling due to the presence of high levels of RAS-GTP. 
Conversely, levels of activated in CRAF were much lower in the BRAF-mutant 
glioma cell lines, consistent with CRAF largely being feedback inhibited. 
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Figure 5-2. Basal RAS-GTP is feedback-inhibited in BRAF-V600E GBM cells. 
Aliquots of whole cell lysates were immunoprecipitated with a GST-tagged RAS-
binding domain of CRAF (GST-CRAF-RBD). The pulldown product (RAS protein 
bound to RAS-GTP exclusively) was subjected to immunoblot analysis with a RAS 
antibody to detect RAS-GTP along with whole cell lysates for the indicated proteins.  
 
After observing that Ras-GTP is feedback inhibited in BRAF-mutant glioma 
cell lines, we next asked if vemurafenib-mediated BRAF inhibition relieved this 
feedback and resulted in a rise in RAS-GTP. To do so, we measured RAS-GTP levels 
over a 5-day time course of vemurafenib treatment in BRAF-mutant glioma cell lines 
(Figure 5-3A). Basal levels of RAS-GTP were low in the DMSO treated samples, as 
before. However, following vemurafenib treatment, we observed a rise in RAS-GTP 
in all three cell lines. This indicates that relief of negative feedback resulted in a rise in 
RAS-GTP levels. This rise in RAS-GTP levels is correlated with insensitivity to 
vemurafenib and an observed rebound in pERK. 
We also quantitated the amount of RAS-GTP relative to total RAS and plotted 
the rise relative to the ratio of RAS-GTP in the DMSO treated samples (Figure 5-3B). 
The rise in RAS-GTP was most dramatic in the AM38 cells, although there was an 
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observable rise in all three cell lines. This rise in RAS-GTP paralleled in the rebound 
in pERK, suggesting that they might be correlated. This would be consistent with 
elevated RAS-GTP levels causing the induction of RAF dimers to which vemurafenib 
is insensitive, resulting in incomplete mutant-BRAF inhibition and a rebound in pERK 
signaling. 
Figure 5-3. Vemurafenib induced RAS-GTP loading in BRAF V600E mutant 
GBM cells. (A) Aliquots of whole cell lysates from cells treated with 2 μM 
vemurafenib for the indicated amounts of time were immunoprecipitated with GST-
CRAF-RBD. The pulldown product was subjected to immunoblot analysis with a RAS 
antibody along with whole cell lysates for the indicated proteins. (B) Graph of the 
ratio of signal intensity of RAS-GTP to total RAS (or vinculin for NMCG1). 
 
Under physiological conditions, either RAS-GTP dependent 
heterodimerization (for example, BRAF/CRAF) or homodimzerization (for example, 
BRAF/BRAF) of RAF proteins is required for RAF signaling (Lavoie and Therrien, 
2015). We therefore wanted to interrogate the constituent members of any RAF dimers 
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formed in the presence of RAS-GTP from vemurafenib induced relief of negative 
feedback. We hypothesized that elevated RAS-GTP levels would likely form mutant-
BRAF/CRAF dimers. To test this, we knocked down CRAF protein in the BRAF-
mutant glioma cell line NMCG1 by generating a stable cell line expressing a 
doxycycline inducible shRNA to RAF1 and then measured the magnitude of pERK 
rebound following a time course of vemurafenib treatment (Figure 5-4A). If our 
hypothesis was correct, we would expect to see that CRAF knockdown would blunt 
pERK rebound as elevated RAS-GTP levels would be unable to induce mutant-
BRAF/CRAF dimers if the cells were depleted of CRAF. 
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Figure 5-4. Depletion of CRAF protein mitigates vemurafenib-induced ERK 
rebound in BRAF V600E mutant GBM cells (NMCG1 cell line). (A) BRAF-
V600E glioma cell lines stably expressing a doxycycline inducible shRNA cassette to 
CRAF were treated with 2 μg/ml of doxycycline for three days, then treated with 2 μM 
vemurafenib for the indicated amounts of time, before being lysed. Whole cell lysates 
were subjected to immunoblot analysis for the indicated proteins. (B) Graph of the 
normalized ratio of signal intensity of pERK to vinculin. 
 
 We observed that with quite potent knockdown of CRAF, we were able to 
partially blunt the rebound in pMEK and pERK. While pERK rebounded as previously 
observed in the cells without shCRAF induction, the magnitude of pERK rebound in 
the cells depleted of CRAF was lower, though there was still a pronounced rebound. 
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From this we conclude that CRAF is likely a component of RAF dimers formed by 
vemurafenib-induced, although probably not the predominant member. 
 Since CRAF seems to play at least a partial role in transmitting RAS-GTP 
dependent signaling and because vemurafenib is unable to inhibit the signaling of 
RAF-dimers, we looked for other BRAF inhibitors that would also be able to inhibit 
RAF dimers. One such compound we identified from the literature is LY3009120 
(Peng et al., 2015).  
 
Figure 5-5. Inhibition of RAF isoforms by vemurafenib and LY3009120. IC50s 
for ARAF, BRAF, and CRAF as measured in in vitro kinase assays or in KiNativ 
Whole Cell Assays. Adapted from Ping SB, Cancer Cell 2015. 
Since CRAF protein seems to play a role in ERK rebound, are there any other 
inhibitors that can inhibit CRAF protein? 
 
We initially compared the selectivity profiles of vemurafenib and LY3009120. 
Vemurafenib shows the highest affinity for BRAF-V600E, with lower affinities 
towards ARAF and CRAF. However, vemurafenib completely fails to inhibit CRAF 
in the KiNative Whole Cell Assay, which measures the ability of compounds to inhibit 
their targets under highly physiological conditions, due to paradoxical activation of 
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BRAF-CRAF heterodimers (Patricelli et al., 2011). In contrast, LY3009120 is able to 
inhibit all RAF isoforms at less than 50 nM, including in the KiNativ Whole Cell 
Assay, indicating that it is a pan-isoform RAF inhibitor. 
We then wanted to determine if LY3009120 could durably inhibit ERK 
signaling, even in the presence of elevated RAS-GTP levels. To do so, we plater 
BRAF-mutant glioma cells side by side into a time of course of vemurafenib and 
LY3009120 and measured both RAS-GTP elevation and pERK (Figure 5-6). While 
the rise in RAS-GTP in the vemurafenib treated cell line was modest (but 
measureable), the increase in RAS-GTP from LY3009120 was quite dramatic. 
Furthermore, despite causing even more elevated RAS-GTP levels, 
LY3009120 was able to durably inhibit ERK signaling, suppressing pERK rebound 
even 5 days after initial treatment. We believe these two observations are completely 
related. By achieving greater suppression of pERK, even more negative feedback is 
relieved, and RAS-GTP becomes even more activated. This means that RAS-GTP 
elevation can be used as a surrogate for pERK suppression. This suggests that drugs 
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that can inhibit RAF dimers are able to suppress pERK rebound in contexts in which 
vemurafenib would in fact result in ERK rebound. 
Figure 5-6. LY3009120 induces less ERK rebound than vemurafenib in BRAF 
V600E GBM cells. Aliquots of whole cell lysates from cells treated with 2 μM 
vemurafenib or with 1 μM LY3009120 for the indicated amounts of time were 
immunoprecipitated with GST-CRAF-RBD. The pulldown product was subjected to 
immunoblot analysis with a RAS antibody along with whole cell lysates for the 
indicated proteins.  
 
 We next wanted to determine if the greater suppression of pERK was 
correlated with greater suppression of ERK activity. To do so, we measured pERK 
rebound and Cyclin D1 expression in BRAF-mutant glioma cells treated either with 
vemurafenib or LY3009120 (Figure 5-7). Cyclin D1 is a direct ERL target can be 
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used to determine the amount of ERK activity in a cell lines. As before, pERK 
rebounded in the vemurafenib treated cells. This was associated with an incomplete 
suppression of Cyclin D1 expression. In stark contrast, LY3009210 was able to 
achieve a much greater suppression of Cyclin D1 expression, even at 5 days after 
initial treatment. 
Figure 5-7. LY3009120 more durably suppresses Cyclin D1 expression than 
vemurafenib in BRAF V600E mutant GBM cells. Immunoblot of whole cell lysates 
from BRAF-mutant glioma cells treated with 2 μM vemurafenib or with 1 μM 
LY3009120 for the indicated amounts of time. 
  
Figure 5-8. LY3009120 more potently suppresses proliferation of BRAF-mutant 
glioma cells than vemurafenib. BRAF-mutant glioma cells were plated various doses 
of vemurafenib or LY3009120 for 5 days, then counted in a trypan blue exclusion 
assay. Normalized cell counts were plotted and the resulting growth inhibition curves 
plotted in Prism Graphpad 
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Finally, after determining that LY3009120 was able to potently suppress 
Cyclin D1 expression, we then wanted to ask if this would translate into greater 
growth suppression (Figure 5-8). We plated a panel of BRAF-mutant cell lines into a 
dose range of vemurafenib or LY3009120 and then counted the number of viable cells 
via a trypan blue assay and compared the effectiveness of the two drugs and inhibiting 
the proliferation of the cell lines. 
LY3009120 was significantly more potent in all three cell lines, with IC50s 
that were approximately 10 fold lower. Furthermore, LY3009120 was also able to 
achieve much more significant growth suppression in AM38 and DBTRG which were 
essentially completely arrested at the higher concentrations of drug. Together, these 
experiments underscore the observation that incomplete pERK suppression is 
associated with incomplete Cyclin D1 expression and insensitivity to vemurafenib. 
However, dimer inhibitor LY3009120 was able to inhibit the dimers formed as a result 
of negative feedback and durably suppress ERK activity. 
Because LY3009120 is a relative new drug, we wanted to try to rule out the 
possibility of off-target effects accounting for the potency we observed. LY3009120 in 
fact inhibits several other kinases at doses 10-20 fold higher than that of BRAF, 
several of which are relevant in gliomas (Figure 5-9A). The doses used in the 
previous experiments quite likely inhibit PDGFRα and PDGFRβ. These genes are 
oncogenes in glioma, so it was important to rule out the possibility that inhibiting 
them was actually what was responsible for the impressive potency of LY3009210. 
 
94 
 
Figure 5-9. Activity of LY3009120 is unlikely due to off-target inhibition on 
PDGFR. (A) IC50 for various kinases measures in in vitro kinase assays. Adapted 
from Peng SB, Cancer Cell 2015. (B) Whole cell lysates from a control cell line and 
BRAF-mutant glioma cells treated were subjected to immunoblot analysis for the 
indicated proteins. Control cell lines is PDGFRα and PDGFRβ-null MEFs stably 
infected with constructs expressing PDGFRα and PDGFRβ and then stimulated with 
PDGF ligand for 5 minutes. (C) DBTRG cells were plated in 1 μM imatinib for 5 days 
and then counted in a trypan blue exclusion assay. Normalized cell counts were 
plotted and the resulting growth inhibition curves plotted in Prism Graphpad. 
 
We measured the levels of PDGFRα and PDGFRβ by immunoblot and 
compared them to a PDGFRα and PDGFRβ null cell engineered to express tagged 
alleles of PDGFRα and PDGFRβ (Figure 5-9B). These cells were then stimulated 
with PDGF for 5 minutes to activate their receptors. The BRAF-mutant glioma cell 
lines express very low to undetectable levels of PDGFRα and PDGFRβ and express 
completely undetectable levels of activated receptor. 
Furthermore, the growth of DBTRG cells is not inhibited by the presence of 
PDGFRα and PDGFRβ inhibitor imatinib. This suggests that any PDGFRα and 
PDGFRβ present is likely dispensable for proliferation. Therefore, it is unlikely that 
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the off target effects of LY3009120 are responsible for its potent activity in BRAF-
mutant glioma. 
In order to provide further evidence for our proof of concept we then asked the 
question that if the mechanism of action of pan-RAF inhibitors like LY3009120 work 
by effectively inhibiting RAF dimers (which vemurafenib does not), would other RAF 
dimer inhibitors also be as effective? To answer his question, we conducted a time 
course comparing pERK rebound and Cyclin D1 repression of vemurafenib to 
BGB659, another BRAF inhibitor that binds both sites of BRAF-mutant dimers with 
equal potency (Yao et al., 2015b). 
Although BGB659 this drug appears to be slightly less potent than 
LY3009120, we still observed a more potent induction of RAS-GTP in the BGB659 
treated cells, suggesting that ERK was more strongly inhibited by BGB559 than it was 
by vemurafenib (Figure 5-10A). We also observed lower Cyclin D1 levels in both cell 
lines, which is also associated with more potent pERK inhibition.  
We also measured the effects of BGB659 in a growth assay. A lower dose of 
dimer inhibitor BGB659 (1 μM) than of vemurafenib (2 μM) was able to more 
potently block proliferation of both AM38 and NMCG1. AM38 had 50% growth of 
the DMSO at 5 days while BGB659 had only 35%. NMCG1 was similar lowered from 
almost 60% to 40%, respectively. Taken together, this suggests that using RAF dimer 
inhibitors should be able to overcome vemurafenib mediated resistance from relief of 
ERK dependent negative feedback. 
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Figure 5-10. BGB659, a drug which binds both sites of mutant BRAF dimers with 
equal potency, also blocks ERK rebound and more potently suppresses growth of 
BRAF-mutant glioma. (A) Aliquots of whole cell lysates from cells treated with 2 
μM vemurafenib or with 1 μM BGB659 for the indicated amounts of time were 
immunoprecipitated with GST-CRAF-RBD. The pulldown product was subjected to 
immunoblot analysis with a RAS antibody along with whole cell lysates for the 
indicated proteins. (B) AM38 and NMCG1 BRAF-mutant glioma cells were plated 
various doses of vemurafenib or LY3009120 for 5 days, then counted in a trypan blue 
exclusion assay. Normalized cell counts were plotted and the resulting growth 
inhibition curves plotted in Prism Graphpad. 
  
 Finally, we wanted to try to represent the utility of RAF dimer inhibitor drugs 
in a more clinical context. Pediatric gliomas often contain BRAF-fusions. However, 
there are few, if any, available preclinical models for these tumor types.  
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To establish a preclinical model, we established a collaboration with Weill 
Cornell, New York Presbyterian, and Memorial Sloan Kettering to receive samples of 
brain tumors resected from pediatric patients. These patients have an extremely high 
prevalence of BRAF:KIAA1549 fusions (Figure 5-1). These fusions have several 
breakpoints across BRAF but always maintain the kinase domain and lose the N-
terminal regulatory domain. These BRAF fusions then spontaneously dimerize, 
resulting in constitutive BRAF activity (Figure 5-11). We hypothesized that these 
patients should benefit from a drug that inhibits RAF-dimer activity. 
 
 
Figure 5-11. Genomic map of breakpoints of BRAF fusions and partners in 
juvenile pilocytic astrocytoma (JPA). BRAF fusions detected in pilocytic 
astrocytoma in all cases result in the loss of the regulatory domain of BRAF and 
constitutive activation of kinase activity. CR – conserved region. Adapted from 
Gronych J, Cell. Mol. Life Sci. (2011) 
 
 When we received these tumor samples in lab, we would then section them 
into 300 μM sections on a vibratome, and then place these tumor sections into 
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different drugs to study their biochemical responsiveness (Figure 5-12A). We 
received a tumor from one such patient, whose MRI is shown in Figure 5-12B. 
Tumors are often presented as suspected as containing a BRAF fusion based on patient 
characteristics like age and tumor location. However, genetic conformation of BRAF 
fusions often is not done until well after a surgery, which necessitates assuming the 
mutational status of a tumor and treating the tumor as such. 
 The tumor we treated in Figure 5-12 ended up being wildtype for BRAF. 
Consistent with this finding, vemurafenib in fact induced pERK signaling in the tumor 
slices, consistent with what would be expect in a tumor signaling with wildtype 
BRAF, which also constitutively signals as a dimer. We also observed that treating the 
tumor with LY3009120 did not result in pERK induction (consider the pERK to total 
ERK signal, as total ERK appears to be higher in the LY3009120 sample). 
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Figure 5-12. Schematic of the ex vivo treatment of surgical JPA tumor samples. 
(A) Patients with suspected JPA have their tumors surgically removed in the operating 
room. Tumor samples arrive in the lab and are cut into 300 μM sections on a 
vibratome. The resulting tumor slices are placed into different drugs for varying 
amounts of time before being lysed and analyzed by immunoblot. (B) MRI of patient’s 
brain tumor. (C) Immunoblot of vibratome slices treated with the drugs indicated for 
24 hours. 
 
While we have yet to be able to treat a BRAF-fusion containing tumor sample 
in this way, this experiment serves as a proof of concept that we will be able to 
analyze BRAF-fusions in their native niche using these tools. 
 
Discussion 
 
The data collected in the earlier experiments establish what has been shown in 
several other contexts, including that elevated BRAF activity is associated with 
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feedback inhibition on RTK and RAS signaling, leading to constitutively low RAS-
GTP levels that cannot support the formation of significant amounts of RAF dimers. 
However, following BRAF inhibition, relief of this negative feedback creates a 
permissive environment for RTK signaling, leading to increased levels of RAS-GTP 
formation and the induction of vemurafenib insensitive RAF dimers.  
However, our data showing that RAF dimer inhibitors can overcome this 
phenomenon and durably inhibit ERK signaling driven by relief of feedback driven 
dimer formation is quite novel, and could have therapeutic impact beyond just BRAF-
mutant glioma or even beyond tumor adaptation to mutant-BRAF signaling. Indeed, 
any tumor driven by RAF-dimers would be expected to respond to a RAF dimer 
inhibitor. For example, pancreatic, lung, ovarian, and thyroid cancers with specific in-
frame deletions near the kinase domain shifts BRAF into a conformation that favors 
spontaneous dimerization have recently been shown to respond to LY3009120 (Chen 
Peng). 
While LY3009120 informs the bulk of the data we’ve shown, it is quite likely 
the more RAF dimer inhibitors with better selectivity profiles and potencies will 
become available. As they are, it will be interesting to compare thier effectiveness and 
therapeutic indices. LY3009120 inhibits RAF monomers and dimers, but is less potent 
again RAS-mutant driven RAF actions. On the other hand, BGB659 only inhibits 
dimers containing mutant-BRAF and actually paradoxically activates wild-type RAF 
dimers, giving it a wider therapeutic index. 
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CHAPTER 6: EXPLORING THE MEK DEPENDENCY OF NF1-
DEFICIENT GBM 
 
Introduction 
 
The most common and well understand of RAS-activating mutations are the 
canonical RAS mutations that impair the intrinsic GTPase enzymatic activity of 
RAS(Cox et al., 2014). These mutations prevent RAS from hydrolyzing bound GTP to 
GDP. However, RAS can also become activated through loss of its GTPase acting 
protein (GAP) NF1. The normal function of NF1 is to catalyze the intrinsic enzymatic 
activity of RAS. However, a certain proportion of tumors have been reported with 
mutations that either delete NF1 protein or impair its catalytic activity, leading to 
impaired regulation of RAS activity. 
RAS has many effector pathways including the RAF-MEK-ERK pathway as 
well as the PI3K/Akt/mTOr pathway, as well as several others. However, repeated 
studies have revealed a MEK dependency in NF1-deficient tumors (Nissan et al., 
2014). Why NF1-deficient tumors seem so dependent on RAF-MEK-ERK signaling 
instead of any of the other RAS effector pathways remains an open question. 
 
Results 
 
In glioma, NF1 mutations occur in the mesenchymal subtype, which are 
especially aggressive and hard to treat The first TCGA project in GBM found 
mutations or allelic loss in NF1 in 18% of tumors recorded, suggesting that NF1 loss 
is a frequent event in GBM (Figure 6-1A). Of almost 1000 tumors in the COSMIC 
database in which an alteration of NF1 was recorded, only about 12% were a point 
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mutation. The rest were frameshift or complex genomic events that completely 
eliminated the allele, or nonsense mutations that prematurely truncated the protein 
(Figure 6-1B). 
Using an inducible NF1 cDNA, we decided to explore the biochemical and 
biological MEK dependency of NF1-defieicnt GBM. 
 
Figure 6-1. NF1 is recurrently mutated in glioblastoma and several other cancers. 
(A) Graph of the frequency of point mutation or copy number loss of NF1 in 
glioblastoma (GBM) and several other cancers as measured in their respective TCGA 
analyses. (B) Graph of the proportion of types of alterations in NF1 recorded in the 
COSMIC database.  
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We first cloned an inducible cDNA of NF1 into the two-vector TET-on T3G 
system from Clontech. This system puts the Tet-operator under the control of a 
constitutive promoter on one vector with one selection marker and the NF1 cDNA 
under the control of the Tet-response element (TRE), allowing for greater size of 
inserts into viral packaging systems, necessary to accommodate the 8.5 kB coding 
sequence of the NF1 gene. Treatment of stable cell lines with doxycycline induces 
expression of the cDNA at the TRE. 
We started by validating the construct biochemically by reconstituting NF1 
function in a variety on contexts and studying its biochemical functions. We initially 
chose U251 cells which have a homozygous frame shift in NF1 that genetically would 
be expected to eliminate the allele. U251 indeed express no detectable NF1 and have 
detectable RAS-GTP (Figure 6-2A, Lane 1). However, after treatment with 
doxycycline, an NF1 antibody-reactive band appears (Figure 6-2A, Lane 2). This is 
associated with a concomitant decrease in RAS-GTP loading. 
We next asked if overexpression of NF1 in a NF1-wildtype cell line would also 
decrease RAS-GTP loading. T98G cells are wildtype for NF1 (Figure 6-2B). Basal 
expression of endogenous NF1 results in lower expression of RAS-GTP. When treated 
with doxycycline, NF1 over-expression results in further unloading of RAS-GTP. 
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 Figure 6-2. A doxycycline inducible cDNA of NF1 restores GTPase activity in 
cell lines with NF1 loss or wild type NF1, but not RAS mutations. Cells with (A) 
biallelic NF1 loss, (B) wild type NF1, or (C) NRAS mutation were infected with a 
doxycycline inducible NF1 expression cassette. Aliquots of whole cell lysates from 
cells treated with 2 μg/ml doxycycline or vehicle for 3 days were immunoprecipitated 
with GST-CRAF-RBD. The pulldown product was subjected to immunoblot analysis 
with a RAS antibody along with whole cell lysates for the indicated proteins. (D) NF1 
deficient TM31 cells were infected with a doxycycline inducible NF1 expression 
cassette. Aliquots of whole cell lysates from cells treated with various dilutions 
doxycycline for 3 days were immunoprecipitated with GST-CRAF-RBD. The 
pulldown product was subjected to immunoblot analysis with a RAS antibody along 
with whole cell lysates for the indicated proteins 
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Finally, to rule out the possibility that the NF1 cDNA could be acting in 
dominant negative manner, we overexpressed NF1 in H1299 cells which harbor an 
NRAS mutation (Figure 6-2C). Induction of NF1 over-expression with doxycycline 
failed to reduce RAS-GTP, consistent with the evidence that RAS-mutants lack 
GTPase catalytic activity that cannot be activated by NF1. 
We also titrated NF1 expression using a dilution series of doxycycline (Figure 
6-2D). Increasing amounts of doxycycline resulted in creased expression levels and 
corresponding decreases in RAS-GTP loading for concentrations of doxycycline up to 
between 1 μg/ml and 3 μg/ml. This indicated that the NF1 construct in inducible 
across a wide range on concentrations of doxycycline. Taken together, NF1 
reconstitution and over-expression result in consistently lower levels of RAS-GTP, 
except in RAS-mutant cells which would not be expect to respond, validating the 
biochemical activity of the construct. 
As a final validation step, we engineered an NF1 mutant with a mutation in the 
GAP-related domain (GRD) that would render the GTPase activity of NF1 
catalytically dead (Figure 6-3). When wildtype NF1 was reconstituted in the NF1-
deficient cell line, total-RAS-GTP decreased. WE also measured the RAS-GTP levels 
of NRAS and KRAS isoforms as well, and each of these was individually unloaded by 
wildtype NF1 reconstituion. When the NF1-R1391S mutation was reconstituted in an 
NF1-deficient cell line, it failed to reduce RAS-GTP levels, indicating that NF1 
mutant was catalytically inactive. 
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Taken together, NF1 reconstitution and over-expression result in consistently 
lower levels of RAS-GTP, except in RAS-mutant cells which would not be expect to 
respond, validating the biochemical activity of the construct. 
 
 
Figure 6-3. Reconstitution of NF1 with inactivating mutations in the RAS-
GTPase domain does not decrease RAS-GTP levels.  Aliquots of whole cell lysates 
from NF1 deficient TM31 cells expressing a doxycycline inducible wildtype, R1391S, 
or K1423E NF1 expression cassette cells treated with 2 μg/ml doxycycline or vehicle 
for 3 days were immunoprecipitated with GST-CRAF-RBD. The pulldown product 
was subjected to immunoblot analysis with a RAS antibody along with whole cell 
lysates for the indicated proteins. 
 
Both mutants are found in GBM while K1423 is also is the catalytic lysine in 
NF1. Reconstitution of wildtype NF1 unloads RAS-GTP while the two RAS-GTPase 
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mutant do not. The RAS-GAP mutants are expressed at lower levels, so it’s possible 
that increasing their expression might uncover residual GTPase enzymatic activity. 
 
Figure 6-4. Reconstitution of NF1 blunts EGF-induced RAS-GTP loading and 
Akt activation. Aliquots of whole cell lysates from NF1-deficient U251 cells 
expressing a doxycycline inducible NF1 expression cassette cells treated with 2 μg/ml 
doxycycline or vehicle for 3 days, serum starved overnight, and then stimulated with 
200 ng/ml EGF for the indicated amounts of time were immunoprecipitated with GST-
CRAF-RBD. The pulldown product was subjected to immunoblot analysis with a RAS 
antibody along with whole cell lysates for the indicated proteins.  
 
 We next sought to try to understand the effects of NF1 reconstitution on the 
RAS-effector pathways RAF-MEK-ERK and PI3K-Akt signaling. We reconstituted 
NF1 expression in U251 cells, starved them overnight, and then conducted a 
stimulation time course with EGF (Figure 6-4). To the cell not treated with 
doxycyclin and that lack NF1 reconstitution, , EGF increased the the loading of RAS-
GTP at 5 and 10 minutes before tapering off. Phosphorylation of Akt-T308 started 
high, and increased through the hour of EGF stimulation. EGF also potently 
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stimulated MEK and ERK signaling with rapidly rose at 5 minutes and then tapered 
slowly throughout the hour. In stark constrant, NF1 reconstitution blunted RAS-GTP 
loading and severly retarded and blunted the activation of pAkt-T308. However, MEK 
and ERK activation appeared to have identical kinetics with and without NF1 
expression. This provides both clear biochemical evidence that NF1 reconsitution is 
functional and also suggests to us that that in these cells, NF1 is not “wired” to alter 
MEK-ERK signaling and instead functions to control PI3K/Akt signaling. 
Figure 6-5. Reconstitution of NF1 does not significantly slow the proliferation of 
two NF1-deficient cell lines. (A) NF1-deficient U251 cells were independently 
infected three times [labeled (1), (2), and (2)] with a doxycycline inducible NF1 
expression cassette. Aliquots of whole cell lysates from parental cells and the 
independently infected cells treated with 2 μg/ml doxycycline or vehicle for 3 days 
were immunoprecipitated with GST-CRAF-RBD. The pulldown product was 
subjected to immunoblot analysis with a RAS antibody along with whole cell lysates 
for the indicated proteins. (B), (C), and (D) The independently infected cells were 
plated into 2 μg/ml doxycycline and the number of viable cells counted by trypan blue 
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exclusion assay at the times indicated. (E) and (F) NF1-deficient YKG1 cells were 
treated as above. 
 
 With such clear evidence for the biochemical activity of NF1 reconstitution, 
we next sought to ask if NF1 reconstitution would also have such a profound effect the 
biology of NF1-deficient cell lines. To test this question, we reconstituted NF1 
expression by infecting U251 cells three independent times, resulting in three different 
levels of reconstituted protein (Figure 6-5A, lanes 4, 6, and 8). In all three cases, NF1 
reconstitution resulted in an unloading of total RAS-GTP, as well as decreases in 
KRAS-GTP and NRAS-GTP. However, in all three cases, there was no significant 
inhibition of proliferation (Figure 6-5B, C and D). We also tried to reconstitute NF1 
in a different NF1-deficient cell line YKG1. Again, despite clear evidence for 
unloading RAS-GTP, we observed no inhibition of proliferation.  
 We also reconstituted NF1 in the NF1-deficient GBM cell line TM31, which 
was isolated from a patient with neurofibromatosis who was born with a germline 
mutation in one allele of NF1. Presumably the tumor received a Knudsen “second hit” 
in NF1 in order to develop a high grade glioma. We reasoned that an NF1-deficient 
tumor isolated from such a patient would be the most likely to retain a dependency on 
NF1 for tumor maintenance. Reconstitution of NF1 in TM31 reduced RAS-GTP 
loading, as in the other NF1-deficient cell lines before. However, NF1 reconstitution 
had a much more pronounced effect on inhibition of proliferation, reducing it about by 
at 50% in two separate trials.  
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Figure 6-6. Reconstitution of NF1 in a GBM cell line isolated from a patient with 
neurofibromatosis unloads RAS-GTP and inhibits proliferation. (A) NF1-
deficient TM31 cells were infected with a doxycycline inducible NF1 expression 
cassette. Aliquots of whole cell from cells treated with 2 μg/ml doxycycline or vehicle 
for 3 days were immunoprecipitated with GST-CRAF-RBD. The pulldown product 
was subjected to immunoblot analysis with a RAS antibody along with whole cell 
lysates for the indicated proteins. (B) and (C) The infected cells were independently 
plated into 2 μg/ml doxycycline or vehicle and the number of viable cells counted by 
trypan blue exclusion assay at the times indicated. 
 
 From these results, we conclude that some, but not all NF1-deficent tumors 
maintain their dependence on NF1-deficient signaling. NF1 mutations are thought to 
be early events in the developments of glioma, so it is possible that NF1-deficient 
signaling is required for tumor initiation, but not for tumor maintenance in certain cell 
lines (Zhu et al., 2005). The observation that a GBM cell line isolated from a 
neurofibromatosis patient retains its NF1-dependency leads us to believe that in 
certain contexts though, it is very possible to retain an addiction to NF1-deficient 
signaling.  
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 We also sought to determine what effect NF1 reconstitution had on MEK 
signaling in NF1 deficient cell lines. In three separate cell lines in which we 
reconstituted NF1 and successfully unloaded RAS-GTP, we did not see any changes in 
MEK or ERK signaling (Figure 6-7). We found this observation somewhat 
unexpected, as cell lines that develop with a MEK dependence as a result of loss of a 
tumor suppressor would be expected to have altered MEK signaling as a result of 
reconstituting that tumor suppressor. 
 With that in mind, we then interrogated the MEK kinase dependence of a panel 
of NF1-deficient cell lines and compared their IC50s to that of BRAF-mutant glioma 
and a BRAF-mutant melanoma cell line, which have a clearly established dependence 
on MEK kinase activity. We measured the growth inhibition of the MEK inhibitor 
trametinib in these cell lines, plotted the growth inhibition curves, and determined 
their IC50s.   
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Figure 6-7. Despite unloading RAS-GTP, NF1 reconstitution in NF1 deficient cell 
lines does effect MEK/ERK signaling. NF1-deficient cell lines were infected with a 
doxycycline inducible NF1 expression cassette. Aliquots of whole cell from cells 
treated with 2 μg/ml doxycycline or vehicle for 3 days were immunoprecipitated with 
GST-CRAF-RBD. The pulldown product was subjected to immunoblot analysis with 
a RAS antibody along with whole cell lysates for the indicated proteins. 
 
Interestingly, the three NF1-deficient cell lines were all sensitive to trametinib, 
but at 20 to 50-fold higher concentrations of trametinib (Figure 6-8A).  The IC50s for 
th eNF1-deficient cell lines were calculated to be between 10 and 20 nM. This was 
consistent with the concentration at which ERK appeared to be inhibited in 
representative acute biochemistry (Figure 6-8B). We also looked at the sensitivity of 
537 cells which were treated with the allosteric MEK inhibitor AZD6244 
(selumetinib) to determine if sensitivity to MEK inhibitors is a universal feature of 
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cancer cell lines. The cancer cell line encyclopedia ranks cell line based on their 
sensitivity to drugs (Figure 6-8C). The green dots represent cell lines with IC50s that 
fall below the maximum concentration of drug used in the assay. We conclude that 
only 15% of the cell line tested showed sensitivity to selumetinib, so it is unlikely that 
response to MEK inhibitors is a universal feature of cancer cell lines. 
 
Figure 6-8. Proliferation of NF1-deficient cells is inhibited at higher 
concentrations of trametinib than is of BRAF-mutant melanoma and glioma. (A) 
The cell lines indicated were plated in various doses of trametinib for 5 days, then 
counted in a trypan blue exclusion assay. Normalized cell counts were plotted and the 
resulting growth inhibition curves plotted in Prism Graphpad. (B) Immunoblot of 
TM31 cells treated with various doses of trametinib for one hour. (C) Plot of range of 
IC50s for allosteric MEK inhibitor AZD6244 for the cancer cell line encyclopedia. 
 
Trametinib is a highly selective allosteric inhibitor. Nevertheless, in order to 
rule out off target effects, we expressed a drug resistant allele of MEK (MEK1-L115P 
or MEK2-L119P; collectively referred to as MEK-LP) and compared its ability to 
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rescue the growth inhibition of trametinib compared to a wild type MEK allele or the 
parental cells (Figure 6-9). 
Figure 6-9. Crystallographic depiction of the L119P MEK inhibitor resistant 
allele. L119 is situated directly within the arylamine pocket to which allosteric MEK 
inhibitors bind. Shown in purple is the MEK inhibitor PD318088 which has a similar 
binding mechanism to trametinib. (From Smith et al. 2011)  
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Figure 6-10. Expression of a drug resistant MEK1 or MEK2 allele is sufficient to 
block trametinib sensitivity in two NF1-deficient cell lines. U251 [(A) and (C)] or 
U87 [(B) and (D)] parental cells where infected with a wild type MEK1 drug resistant 
MEK1-L115P [(A) and (B)] or wild type MEK2 or drug resistant MEK2-L119P [(C) 
and (D)]. The cell lines were then plated in various doses of trametinib for 5 days, then 
counted in a trypan blue exclusion assay. Normalized cell counts were plotted and the 
resulting growth inhibition curves plotted in Prism Graphpad. Immunoblots of each 
cell line treated with trametinib are shown. 
 
Overexpression of a wild type allele of MEK only provided a very slight 
rescue (Figure 6-10). In contract, expression of a drug resistant MEK1-L115P or 
MEK2-L119P allele is sufficient to completely rescue trametinib sensitivity in both 
cell lines at concentrations up to 200 nM trametinib, indicating that the trametinib 
IC50s for the NF1-deficient cell lines in the 20 nM range is an on target effect.  
There is residual pERK signaling in the MEK-LP cells indicated that 
trametinib binding in inhibed and cannot inhibit pERK remains even at very high 
doses of trametinib (10 times the IC50 of the NF1-deficient cell lines) and is 
associated with continued proliferation. In contract, pERK is inhibited in the parental 
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and wild type MEK expressing cells at 20 nM in most cell lines and at 200 nM in all 
cell lines. Together, this suggests that NF1-deficient cell lines maintain their MEK 
sensitivity, but can uncouple it from their NF1-dependency and ability to affect MEK 
signaling. 
 
Discussion 
 
 The canonical roles of NF1 signaling are well established. Guanine exchange 
factors (GEFs) activate RAS loading while GAPs counterbalance their activity. 
Activated RAS can then signal to one or more of its effector pathways. However, as 
with so many other things in cancer, these canonical pathways do not always directly 
translate to the wiring of oncogenic signal pathways. 
 We provided direct evidence that NF1 does not alter the biochemical signaling 
of MEK or ERK by reconstituting NF1 in a variety of NF1-deficient cell lines, 
including those that are dependent on NF1 for tumor maintenance, and observing that 
pMEK and pERK do not change. However, we also showed that NF1-deficient cell 
lines can maintain a dependence on MEK kinase activity and that this dependence is 
not a universal feature of cancer cell lines. This suggests that NF1-deficient GBM can 
disconnect their MEK kinase dependency from their biochemical dependency on NF1. 
 
 
 
 
 
 
 
117 
 
APPENDIX A: MATERIALS AND METHODS 
 
Cell lines and culture conditions 
 
 Cell lines were sequenced on an Illumina MiSeq for a panel of genes selected 
by our laboratory, including ARAF, BRAF, RAF1, HRAS, NRAS, KRAS, NF1, 
MAP2K1, MAP2K2, MAP3K1, and MAP3K2 and the MSKCC Integrated Genomics 
Core. 
 
Cell Line Reference 
Cell Line 
Name 
Source Method of 
obtaining 
Product 
Number 
Culture Media Ref. 
A375 A-375 ATCC Purchase CRL-1619 DMEM+10% 
FBS with 
antibiotics 
(Giard et 
al., 1973) 
AM-38 AM-38 JCRB Purchase IFO50492 MEM+10% 
FBS with 
antibiotics 
(Izumi et 
al., 1994) 
293T Lenti-X 
293T  
Clontech Purchase 632180 IMDM+10% 
FBS with 
antibiotics 
(n/a) 
DBTRG DBTRG-
05MG 
ATCC Purchase CRL-2020 DMEM+10% 
FBS with 
antibiotics 
(Kruse et 
al., 1992) 
NMCG1 NMC-G1 JCRB Purchase IFO50467 DMEM+10% 
FBS with 
antibiotics 
(Naruo et 
al., 1993) 
KG1C KG-1-C JCRB Purchase JCRB0236 DMEM+10% 
FBS with 
antibiotics 
(Miyake, 
1979) 
H1299 NCI-H1299 ATCC Purchase CRL-5803 RPMI+10% 
FBS with 
antibiotics 
(Giaccone 
et al., 
1992) 
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HCT116 HCT 116 ATCC Purchase CCL-247 McCoy+10% 
FBS with 
antibiotics 
(Brattain et 
al., 1981) 
SKMEL239 SKMEL-
239 
Rosen 
Lab 
Gift (n/a) RPMI+10% 
FBS with 
antibiotics 
(n/a) 
MALME3M Malme-3M Rosen 
Lab 
Gift (n/a) RPMI+10% 
FBS with 
antibiotics 
(n/a) 
SKMEL264 SKMEL-
264 
Rosen 
Lab 
Gift (n/a) RPMI+10% 
FBS with 
antibiotics 
(n/a) 
Hth104 Hth104 Rosen 
Lab 
Gift (n/a) RPMI+10% 
FBS with 
antibiotics 
(n/a) 
8505C 8505C Rosen 
Lab 
Gift (n/a) RPMI+10% 
FBS with 
antibiotics 
(n/a) 
HT29 HT-29 Rosen 
Lab 
Gift (n/a) McCoy+10% 
FBS with 
antibiotics 
(n/a) 
 
Cells were maintained under antiseptic conditions in a water jacketed incubator 
with a 5% CO2 atmosphere. Media was supplemented with the antibiotics Primocin 
(100 μg/ml; Invivogen Product #ant-pm-2) and Normocin (100 μg/ml; Invivogen 
Product #ant-nr-2). All media (except Opti-MEM) was purchased from and made by 
the MSKCC Media Preparation Facility. Opti-MEM was purchased from 
ThermoFisher Scientific (Product #31985070). HyClone Fetal Bovine Serum (FBS) 
(GE Life Sciences; Product #SH30071.03) was added at 10% of the original volume 
of media. All additives (except drugs) were added and then passed through a sterile 
0.22 μM filter (EMD Millipore Product# SCGPU05RE). 
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Western Blotting 
 
 Cell lysates were collected in Phosphate Buffered RIPA (Boston Bioproducts; 
Product #BP-415) which contains 10 mM Sodium Phosphate, 150 mM NaCl, 1% 
Triton X-100, 0.5% Sodium deoxycholate, and 0.1% SDS, pH 7.2. Benzonase 
nuclease (Sigma-Aldrich; Product #E1014-5KU) was added at 1000X Halt Protease 
and Phosphatase (ThermoFisher Scientific; Product #78440) was added at 100X. 
Lysates were clarified by spinning in a benchtop centrifuge at maximum speed for 10 
minutes at 4˚C. Protein concentration was determined by DC Protein Assay (Bio-Rad; 
Product# 5000111) with standards diluted in Phosphate Buffered RIPA. Samples were 
normalized in 4X NuPAGE LDS Sample Buffer (ThermoFisher Scientific; Product 
#NP0008) to which 8% β-mercaptoethanol (Sigma-Aldrich; Product #M3148-25ML) 
was added before normalizing or Laemmli SDS-Sample Buffer – Reducing (6X) 
(Boston Bioproducts; Product #BP-111R). Samples were heated at 70˚C for 10 
minutes. Depending on protein concentration, 20-50 μg of protein were loaded onto a 
NuPAGE Novex 4-12% Bis-Tris Protein Gels and run at 200V constant for 55 
minutes. Gels were transferred using a Bio-Rad Trans-Blot wet transfer apparatus for 
1 hour at 95 V constant submerged under ice, 2 hours at 65 V constant at 4˚C, or 
overnight at 35 V constant at 4˚C. 
 Membranes were blocked in Odyssey Blocking Buffer (Li-Cor; Product #927-
40000) for at least one hour. Membranes were incubated in antibodies (cataloged 
below) diluted 1:250-1:1000 in Odyssey Blocking Buffer with 0.1% Tween-20 for at 
least one hour at room temperature with shaking, or overnight with shaking. 
Membranes were washed at least three times in TBS with 0.1% Tween-20 (TBS-T) for 
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at least 5 minutes per wash. Blots were incubated with IRDye 680RD Goat anti-
Mouse IgG  (Li-Cor; Product #926-68070) and IRDye 800CW Donkey anti-Rabbit 
IgG (Li-Cor; Product #926-32213) dilted 1:10,000 in Odyssey Blocking Buffer with 
0.1% Tween-20 for at least 30 minutes at room temperature with shaking. Membranes 
were washed at least three times in TBS-T for at least 5 minutes per wash.  
Membranes were rinsed in Milli-Q (or equivalent) purified water before being imaged 
on a Li-Cor Odyssey Infared Imaging Scanner. 
 Antibodies against ERK1/2 (#9102), phospho-ERK1/2 (#9101), Akt (#2920), 
phospho-Akt-S473 (#4060), phospho-Akt-T308 (12038) BRAF (#9434), CRAF 
(#9422), phospho-CRAF S338 (#9427), phospho-CRAF S289, S296, S301 (#9431), 
phospho-MEK1/2 (#9154), Cyclin D1 (#2978), EGFR (#4267), HER2 (#4290), HER3 
(#12708), HER4 (#4795), phospho-EGFR-Y1068 (3777), phospho-HER2-Y1221-
Y1222 (#2243), phospho-HER3-Y1289 (#2842), phospho-HER4-Y1284 (#4757), 
phospho-S6 Ribosomal Protein-S235-S236 (#8207) were purchased from Cell 
Signaling Technology. Vinculin was purchased form Sigma-Aldrich (#V9131). Ras 
antibody was obtained in Ras-GTP kit (described below). 
 
Drugs 
 
 Vemurafenib (#S1267) and trametinib (#S2673) were obtained from Selleck 
Chemicals. LY3009120 and BGB-657 were gifts from the Rosen laboratory. Drugs 
were diluted in anhydrous DMSO to a 10 mM stock (except trametinib which was 
diluted to a 1 mM stock) before being further diluted in DMSO to 1000X times the 
concentration to be used in the assay (for a final concentration of 0.1% DMSO in 
media). Doxycycline (dox) was obtained from Boston Bioproducts (#ABT-265). 
Puromycin was obtained from Invivogen (#ant-pr-1). 
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In-Cell Western 
 
 In-Cell Western was performed according to manufacturer’s instructions. 
Briefly, cells were plated in a clear bottomed, black-walled plate (BD Falcon; Product 
#353948) and treated for drugs in the concentrations indicated. Media was removed 
and cells were fixed in 4% methanol-free paraformaldehyde (ThermoFisher Scientific; 
Product #28906). Cells were simultaneously permeabilized and washed five times 
with PBS containing 0.1% Triton X-100 before being blocked in Odyssey Blocking 
Buffer. Primary antibody incubation, washing, secondary antibody incubation, and 
imagine were performed as above.  
The average and standard error of the mean were plotted in GraphPad Prism. 
For experiments in which an IC50 was to be calculated, data normalized to percent 
response of vehicle were fit with a log(inhibitor) vs. response (three parameter) non-
linear regression for experiments with 5 or fewer doses including vehicle, or a 
log(inhibitior) vs. response—variable slope (four parameter) for experiments with 6 or 
more doses. 
 
 
RAS-GTP Pulldown Assay 
 
 RAS-GTP assay was performed according to manufacturer’s instructions. 
Briefly, lysates were collected in 1X Lysis/Binding/Wash Buffer with 100X Halt 
Protease and Phosphatase inhibitor cocktail added, then clarified, and quantitated. 
Equal amounts of protein (500-1000 μg) were added to pre-washed glutathione resin 
with 80 μg GST-Raf-RBD. Samples were incubated at 4˚C with rotation before being 
122 
 
washed three times in 1X Lysis/Binding/Wash Buffer with 100X Halt Protease and 
Phosphatase inhibitor cocktail added. Bound RAS was eluted with reducing 1.2X 
Sample Buffer before being heated at 70˚C for 10 minutes. Eluted protein was run as 
described above in Western Blotting section using kit provided RAS antibody for 
detection. 
 
Cellular Proliferation Assays 
 
 Cells to be plated were trypsinized and counted. Depending on the growth rate 
of the cell lines, 0.1x106-0.3x106 cells were plated in a 6cm dish inn at least triplicate. 
For experiments in which an IC50 was to be calculated, cells and their media were 
trypsinized/collected, spun down, and counted on a Beckman Coulter Vi-Cell XR Cell 
Viability Analyzer (trypan-blue bases cell viability assay in which live cells exclude 
the dye outside their cell membranes) after 5 days in drug. For cells in which 
proliteration over time was measured, cells were collected and counted as above for 
the indicated amounts of time. 
The average and standard error of the mean were plotted in GraphPad Prism. 
For experiments in which an IC50 was to be calculated, data normalized to percent 
response of vehicle were fit with a log(inhibitor) vs. response (three parameter) non-
linear regression for experiments with 5 or fewer doses including vehicle, or a 
log(inhibitior) vs. response—variable slope (four parameter) for experiments with 6 or 
more doses. 
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Generation of cell lines 
 
 pTRIPZ constructs contains doxycycline inducible short hairpin RNAs 
(shRNAs) targeting human BRAF (#V2THS_240239) and CRAF (#V3THS_303540) 
were purchased from Dharmacon. pENTR-NF1 was a gift from Karen Chichowski at 
Harvard. 
 
BRAF Mature Antisense:
 TAGTGAGCCAGGTAATGAG 
CRAF Mature Antisense:
 ACTGCAACATCTCCGTGCC 
 
 Stable cell lines with dox inducible shRNA to BRAF or CRAF were generated 
by producting lentivirus in 293T by cotransfecting packaging plasmids pMD2G and 
pSPAX2 using Lipofectamine 2000 (ThermoFisher Scientific; Product # 11668019) 
according to manufacturer’s protocol in Opti-MEM media. Transfection mixture was 
added dropwise to 90% confluent 293T cells in Opti-MEM media. Transfection 
mixture was incubated overnight before media was changed to IMDM + 10% FBS. 
Cells were incubated for 24 hours before lentivirus containing supernatant was 
collected and filtered through a 0.44 μM Steriflip vacuum filter (EMD Millipore; 
Product # SE1M003M00). This collection process was then repeated 24 hours later. 
 Filtered supernatant was supplemented with 1000X hexamethrine bromide, 
1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide (Polybrene from Santa-
Cruz Biotech; Product #sc-134220) and added to cells to be infected overnight. The 
next morning media was changed to normal growth media. Cells were infected 
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overnight a second time before being selected in 2-10 μg/ml puromycin for 2-5 days, 
or until uninfected parental cells are completely dead). 
 
Cell cycle analysis 
 
 Cells were treated with drugs for the indicated amounts of time before being 
trypsinized, washed, fixed, and permeabilized with saponin containing BD 
Cytofix/Cytoperm according to manufacturer’s protocol before being stained with 
Hoechst 33342 (NucBlue from ThermoFisher Scientific; Product #R37605) and 
analyzed for DNA content/fluorescence on a flow cytometer. Corresponding peaks 
were analyzed in FlowJo to determine cell cycle phase. 
 
RNA isolation and cDNA library preparation 
 
 RNA was isolated from cells in RLT Buffer (RNeasy from Qiagen; 
Product74104) and run through a QIAshredder column (Qiagen; Product #79654) to 
shear genomic DNA, and then isolated according to kit instructions. RNA was eluted 
in water and the concentration determined on a Nanodrop Analyzer. 
 RNA for RNAseq experiments was processed as described below. 
 RNA for quantitative PCR was normalized to 1.0 μg per reaction and cDNA 
libraries generated with iScript cDNA Synthesis Kit (Bio-Rad; Product #1708891) 
according to kit instructions. cDNA was then diluted 1:5 in nuclease free water before 
being used in QPCR experiments.  
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RNAseq 
 
RNAseq was performed by the MSKCC Integrated Genomics Core. Briefly, 
double stranded cDNA libraries were prepared from submitted RNA, digested by 
DNase I to form double stranded cDNA fragments, ligated to Illumina adaptors, 
amplified by PCR, and then high-throughput sequenced with 50 base pair reads for 40 
million reads. 
 
Quantitative PCR 
 
cDNA libraries were analyzed on a QuantStudio 6 Flex Real-Time PCR 
machine using ABsolute Blue QPCR Mix (ThermoFisher Scientific; Product #AB-
4139/A) which contains the passive dye ROX. RNAs were quantitated using the ΔΔCt 
method and normalized to Large Ribosomal Protein (RPLPO) using TaqMan 
chemistry (VIC probe/MGB quencher, primer limited). Primer probe pairs for genes 
were ordered from ThermoFisher Scientific and are cataloged below. 
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Gene Catalog number 
NRG4 Hs00945535_m1 
EPGN Hs04334113_m1 
HBEGF Hs00181813_m1 
EGF Hs01099999_m1 
TGFA Hs00608187_m1 
AREG Hs00950669_m1 
EREG Hs00914313_m1 
BTC Hs01101204_m1 
NRG1 Hs00247620_m1 
NRG2 Hs00171706_m1 
NRG3 Hs01377907_m1 
NRG4 Hs01076090_m1 
EGFR Hs01001580_m1 
ERBB2 Hs00176538_m1 
ERBB3 Hs00955525_m1 
ERBB4 Hs00955511_m1 
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